KOREA INNOVATIVE PHARMACEUTICAL

COMPANY

2015

32

Aging populations and growing interest in health and welfare continue to drive up the demand for innovative drugs across the world. Globally, R&D spending in the pharmaceutical industry was higher than any other industry (pharmaceutical and bio ranked No. 1 with KRW 126 trillion, according to the data released by Department for Business, Innovation and Skills in UK), indicating that the future industrial structure is shifting from IT to pharmaceutical business.

Pharmaceutical Industry in Korea

In Korean wons, the value of drugs manufactured in Korea was KRW 16.3 trillion in 2013. The annual average growth rate for the past five years was 2.6 percent. In addition, the size of the pharmaceutical market was KRW 19.3 trillion in 2013.

Size and Market Trends in Pharmaceutical Industry in Korea (Unit: KRW Trillion, %)

Category Production Export Import Balance Market size YoY Growth Rate2009 14.8 1.8 5.2 △3.4 18.2 6.02

2010 15.7 1.8 5.4 △3.6 19.3 6.18

2011 15.6 1.9 5.5 △3.6 19.1 -0.94

2012 15.7 2.3 5.9 △3.5 19.2 0.32

2013 16.4 2.3 5.3 △2.9 19.3 0.57

Note: 1) Pharmaceutical products include finished products, narcotic drugs, ultra narcotic, psychotropic substance and drug substance

2) Numbers in export and import categories are calculated in Korean won and converted US dollar by using annual average exchange rate at Bank of Korea

Source: 2013 Pharmaceutical Industry Statistics, Korea Pharmaceutical Manufacturers Association (KPMA)

Facts & Survey Report, 2013, Korea Pharmaceutical Traders Association (KPTA)

Based on its technological competitiveness and quality drugs, the pharmaceutical industry in Korea has taken a stride in strengthening its ability to develop innovative drugs in a short period of time, including R&D, clinical trials and drug manufacturing. Impressive growth made in the last few years suggests that Korea-based pharmaceutical companies are ready to take a leap forward as global players.

[R&D] Development of innovative medicines and strong pipelines across various therapeutic areas

The local pharmaceutical industry began to manufacture both finished products and drug substances in the 1960s, and developed new processes in the 1980s. Following the early phase of drug development in the late 1980s, Korean pharmaceutical industry began to develop innovative drugs in the 2000s, and has successfully developed some innovative and incrementally modified drugs since then. Since the introduction the chemical compound patent system in 1987, the number of innovative drugs introduced in the country has also increased at a very fast pace. Korea has seen development of innovative drugs across various therapeutic areas, from “Sunpla Injection,” a treatment for stomach cancer developed by SK Pharmaceuticals in 1999 to “Sivextro” developed by DONG-A ST in 2015. So far, Korean pharmaceutical

Potential of Pharmaceutical Industry in Korea

32

companies have developed therapies in an array of areas including oncology, antibacterial, gastritis, respiratory infections, duodenal ulcer, diabetic foot ulcer, erectile dysfunction, hepatitis B and hypertension.

Drug Development in Korea

[Clinical Trials] Clinical trials grew dramatically from both qualitative and quantitative perspectives

Already on a clear growth track with its high level of clinical trial capabilities and reliable data, Korea is emerging as a core clinical trial destination in the pharmaceutical market in Asia. Seoul-based 13 major healthcare organizations, including Seoul Nat’l University Hospital, Samsung Seoul Medical Center and Asan Medical Center, have won global certifications for their clinical study environment helping the country to build a clinical infrastructure on a global level. With this advanced infrastructure, Seoul became the third largest host city for global clinical trials, following Houston and San Antonio in the United States, in 2009. Seoul was also selected as Asia’s No. 1 destination for clinical trials in 2008 (338 cases in Korea, 135 in Singapore and 36 in Japan).

The number of multinational regional clinical trials (MRCTs) conducted by multinational pharmaceutical companies in Korea has also increased sharply since the country introduced International Conference on Harmonization Good Clinical Practice (ICH GCP) in 2000. Especially, Pfizer formed a partnership with Korea as part of its global clinical program in 2008, selecting 4 of its 9 global Core Research Sites (CRSs) in Korea.

[Manufacturing] High level of competitiveness and ability to generate rich pipelines of innovative drugs

Pharmaceutical companies in Korea have been working to ensure that their drug manufacturing facilities meet rigorous global standards. To reflect global trends, the guidelines on Good Manufacturing Practices (GMP) changed from dosage forms to prior approval of individual items in 2008. As the guidelines shifted from management of

1960/70’s1980’s

1990’s2000’s

2010’sLocal manufacturing of finished products and

drug substance

Development of new processes

Early years of drug development

Drug development getting on track

Development of innovative drugs targeting

the global market

Launch of innovative drugs (total of 23)

Sunpla

’99 ’02

Factive

’06

Levovir

’08

Noltec

’13

Duvie

’07

Pelubi

Mvix

’05

Revanex

Zydena

’12

Supect

Zemiglo

’01

EGF

Milican

Q-roxin

’03

Apitoxin

Peudovaccin

Camtobell

’10

Pyramax

Kanab

Zepeed

’14

Riavax

2015

Acelex

Zabolante

Sivextro(Tab.)

Sivextro(Inj.)

54

National Pharmaceutical R&D Support

▶ Total government healthcare R&D : $400M▶ Total government pharm. R&D : $250M▶ Total MoHW pharm. R&D : $130M

Clinical Trial Capability

▶ Seoul, the capital of South Korea, ranks #1 for industry sponsored clinical trials among all cities worldwide (2013)

▶ Korea ranked as 10th in the world for Industry sponsored clinical trials

World Class GMP & DDS Technology

▶ cGMP & EU GMP standard facilities▶ Innovative Drug Delivery Systems

• Film-type Viagra and patch-type Alzheimer's and Parkinson’s drugs developed, etc

High Growth in Export

▶ ’08~’12, 16.5% CAGR for Drug Export• US $2,300 M export (’12)

Globalization

▶ Joining PIC/S (expected in July, 2014) ▶ 20 WHO PQ products developed (’13)

• 13 vaccines, 3 drugs, 4 diagnostic reagents▶ Joint worldwide marketing of K-pharma developed drugs

with MNCs• Boryung’s Kanarb® for hypertension (Fimasartan)• Celltrion’s Remsima® Inj. (Inflixmab)• Hanmi’s Amosartan® for hypertension and• Esomezol® for esophageal reflux disease• JW’s 3 chamber IV solution

Plant Construction

▶ Construction of pharma clusters in Saudi Arabia and UAE based on G2G cooperation under discussion• The countries want K-Pharmas to participate in their pharma cluster projects • ‘Cloning Project’ : SA wants to build exactly same anticancer

plant as K-pharma’s one▶ IV Solution Plant of JW Pharm

• Plant Construction Order in Kazakhstan▶ Blood Fractionation Plant of Green Cross Corp

• Contract with the Thai Red Cross

Top Class Bio-Pharma Competency

▶ High quality bio products (1st stem cell therapy, 1st biosimilar approved, 20 biosimilar clinical trials undergoing)

▶ Stem cell (Clinical trials 2nd, Patent 4th, # of Researcher 5th, SCI Papers 8th in the world)

▶ Stable supply of Vaccines• Self supply for essential vaccines• 5 premium vaccines in Clinical Trials (Phase 1, (PCV, HPV, Rotavirus, Herpes zoster, Cholera))

New Drug Release Competency

▶ 20 New Drugs, 33 IMD products approved▶ 2~3 New drugs coming out to the market every year

dosage forms to that of individual items based on a step-by-step process through 2010, the quality assurance system for domestically manufactured drugs reached a global level.

In addition, Korea has the ability to conduct drug R&D for compounds and commercial technologies, including organic synthesis, agents and global clinical trials. This ability was gained through development of generics and incrementally modified drugs. Korea is also a leader in the pharmaceutical biological technology area. With fruitful results from R&D including development of the world’s first stem cell therapy and xenotransplantation of pancreatic ducts, Korea is in an advantageous position to be a leader in promising future industries. The level of therapeutic technologies in cardiac surgery and management, and cervical cancer in Korea is the best among other OECD countries, according to OECD Health Data 2009.

Korea pharmaceutical industry is shifting its focus from the domestic market to the global market, and the world now pays attention to Korean pharmas as successful partners.

Korean Pharmaceutical MarketKRW 19 Trillion(USD 17 Billion, ‘13)

▶ 2% of the World Market (13th)▶ Around 5.9% Average Annual Growth (’07 to ’12)▶ Only 25% MNC dominated (reimbursement price based, ’12)▶ 680 Manufacturers (257 for finished drugs)

54

Korea aspiring to transforming itself into one of the top seven pharmaceutical powerhousesKorea has designated the pharmaceutical industry as one of the future growth engines. In order to foster the industry, the Korean government has been placing emphasis on enhancing growth potential through far-reaching policy measures, ranging from technology innovation to promoting market transparency, boosting global competitiveness of companies, and establishing infrastructure for sustainable development. Moreover, with knowledge and capacity mustered, the government, industry, medical society, and academic community are devoting themselves to make a leap forward into global markets.

Under the circumstance where the Korean population has been aging rapidly, the Korean government has keen interest in the pharmaceutical industry, which serves as a foundation for the quality of life of the public. The government introduced “Accreditation of Innovative Pharmaceutical Company” in 2012, and will reinforce its efforts to support the industry every year with a view to reinventing the nation into one of the top seven pharmaceutical titans.

Introduction of Promotion and Support of Innovative Pharmaceutical Company

What Company Can Be an Innovative Pharmaceutical Company? Special Act on Pharmaceutical Industry Promotion and Support (enacted in March 2011) serves as the legal foundation to designate innovative pharmaceutical companies verified to possess high R&D capacity for new drug development and to be globally competitive. Those companies are expected to play a leading role in developing the domestic pharmaceutical industry into a future growth engine.

Accreditation Process The Accreditation Screening Committee conducted written and verbal evaluations on candidate pharmaceutical firms which met the requirements (Article 2 of the Enforcement Decree of the Special Act: investment volume over a certain level). In the evaluations, the committee assessed candidate companies based on specific requirements, such as R&D performance in the past, company’s capacity, vision and investment plan, ethical business practice, etc. The results of the evaluations delivered by the screening committee were finalized after the review carried out by the Committee for Pharmaceutical Industry Promotion and Support, which is chaired by the Minister of Health and Welfare.

Composition of Designated Innovative Pharmaceutical Companies• 31 general pharma firms: 31 leading firms that have marked high scores in terms of R&D investment as well as researchers,

manufacturing facilities, patent and license-out, and overseas market advancing plus ten SMEs that have built on expertise in specialized areas such as development of incrementally modified drugs

• Seven bio venture companies: firms with relatively low sales but highly competitive technology and creative business models• Two local corporations of a multinational pharma firm: one local company of an MNC considered outstanding

in terms of R&D investment (in early clinical trials), local production performance, overseas market advancing, etc.

List of Companies Certified as Innovative Pharmaceutical Companies [40]

Category Name of Company

General pharma firms [31]

Ahngook pharm.co.Ltd, Boryung Pharmaceutical co., Ltd., Bukwang Pharmaceutical Co., Ltd., Celltrion, Inc., Chong Kun Dang Pharmaceutical Corp., CJ HealthCare corporation, Dae Hwa Pharmaceutical Co. Ltd., Daewon Pharmaceutical Co., Ltd., Daewoong Pharmaceutical Co., Ltd., Dongkook Pharmaceutical, Green Cross Corp., HanAll BioPharma Co. Ltd., HANDOK Inc., HANLIM PHARM. CO., LTD., Hanmi Pharmaceutical. Co., Ltd., HUONS CO., LTD., Hyundai Pharmaceutical Co., Ltd., IL-YANG PHARMACEUTICAL CO., LTD., ISU ABXIS, JW Pharmaceutical Corp., Kolma Korea Co., Ltd., Korea United Pharm. Inc., Kuhnil Pharmaceutical Co.,Ltd, LG Life Sciences, Ltd., Samjin Pharmaceutical Co., Ltd., Samyang Biopharmaceuticals Corporation., SHIN POONG PHARM. CO., LTD, SK Chemicals Co. Ltd., ST Pharm Co., Ltd., TAEJOON PHARM. CO., LTD., Yuhan Corporation

Bio venture companies [7] BCWORLD PHARM. CO., LTD., BIONEER CORPORATION, CrystalGenomics, Inc., GemVax & KAEL Co., Ltd., Genexine, Inc., Medytox, ViroMed Co., Ltd

Local corporation of a multinational pharma firm [2] Korea Otsuka Pharmaceutical Co.,Ltd., sanofi-aventis Korea

Public-private Partnership for Development of Pharmaceutical Industry Contributing to Global Health

Pharmaceutical

Pharmaceutical

76

Anycough Cap.

For a Better Life

Ahngook pharm.co.Ltd

The 50 years old leading R&D oriented Korean pharmaceutical manufacturer/Distributor/Exporting/licensor company.

Mainly focusing on Respiratory/GI/Cardio/NSAID. Nominated as one of the leading innovative R&D company in Korea by government. A variety of licensing/importing opportunity (New Antitussive/Expectorant, Modified GI modulator/Chiral PPI tablet form, Syrup type Dexibuprofen and so on)Ahngook pharm is the top respiratory field market leader in Korea with Synatura syrup and Anycough cap.Not only Ahngook has been focusing on respiratory syrup but also big market player in cardiovascular field with Levotension (S-amlodipine tablet). Also, Ahngook has been launching new and differentiated drugs in the market with strong R&D capability.Ahngook’s financial status is very sound and stable with sound cash flow and profit.Likewise, Ahngook is one of the most promising pharmaceutical companies in Korea.

Brief Company Profile

Brief History of AhngookYear Milestones1959 Established1969 Mr. June-Sun Auh joined as President1986 Completion of the Korea GMP Facility1994 Launching of Tobicom-s(Eye-nutrient) / Selected as ‘the HIT product’ of the year1998 Mr. Jin Auh was named CEO & President2000 Launching of Prospan and Listed on KOSDAQ2005 Approval of BGMP synthetic Facility by KFDA2006 Launching of Levotension (the first S-amlodipine in Korea) for the treatment of hypertension

2009Groundbreaking of New GMP facilities“Anycough”(Novel Antitussive) was launched in July, 200950th Anniversary ceremony held

2010 Out-licensing of Anycough to Biocopea (UK), June 7th. 2010

2011Launching of Synatura, new herbal formulationCo-Promotion agreement for Zaditen of Novartis KoreaCo-Promotion agreement for Harnal-D(BPH) and Vesicare(OAB) of Astellas Korea

2012 In-licensing of Lupapin & Export MOU of Synatura Nominated as ‘the innovative pharmaceutical company’ by Korean Ministry of Health.

CONTACT US

James S.Y.CheonVice President / Global Business Division• Phone : +82-2-3289-4348• Fax : +82-2-849-4123• E-mail : jsycheon@ahn-gook.com

· Company Ahngook pharm.co.Ltd· CEO Jin Auh· Specialty Pharmaceutical Manufacturer, Distributor, Exporter · Location 993-75, Daelimdong, Yongdeungpo, Seoul, Korea· Homepage www.ahn-gook.com

Levotension Tab.

Letopra Tab.

Synatura Syrup

· Founded in 1959· Main Business areas : Pharmaceuticals, Diagnostic Medical Devices, Cosmetics and Export· Sales : KRW 121 Bil.(USD 110 M in 2011)· Employees : 471 Persons

· HQs is located in Seoul· Central Reseach Center and General Plant are located in Gyeonggi-do· Representatives - Mr. June-Sun Auh : Chairman - Mr. Jin Auh : CEO & President

Pharmaceutical

Pharmaceutical

76

BCWORLD PHARM is a technology-driven pharmaceutical company in Korea whose expertise in formulation and process development enables it to provide quality generics as well as value-added novel formulation products.

BCWORLD PHARM strives to establish its position as a pioneer in developing value-added pharmaceuticals through cutting-edge formulation technology including immediate/controlled release as well as fast-dissolv-ing DDS, combined formulation, gastro-retentive system and depot formulation by way of proactive invest-ments in R&D and strategic alliances.

Recently BCWORLD PHARM not only has been certified as Korea Innovative Pharmaceutical Company (KIPC) by Korea Ministry of Health & Welfare but also designated as Advanced Technology Center (ATC) by Korea Ministry of Knowledge Economy.

Main ProductsTherapeutic Class Products

Antibiotics (Carbapenem) Mepem Inj., Cilacin Inj. etc.Anti-Infectives Merogel Gel, BC Itraconazol Tab., etc.Hyperlipidemia Starova Tab., BC Atorvastatin Tab. etc.

Anti-Osteoporosis Agents Pamiron Inj., Risidro Tab.Anti-Hypertensives Ibertan Tab., Ibertan Duo Tab., Duomax Tab. etc.

GI Agents Mucopid Tab., BC Ranitidine Inj. etc.Narcotics Remiba Inj., BC Morphine Sulfate Inj., BC Fentanyl Inj. etc.

R&D PipelineCategory Item Indications Stage

GRS BCWP_A001 Antibiotic Phase I (Korea)Combination BCWP_C001 Hyperlipidemia PreclinicalMicrosphere BCWP_D001 Anti-cancer FormulationMicrosphere BCWP_D003 Anti-cancer PreclinicalMicrosphere BCWP_D009 Schizophrenia PreclinicalMicrosphere BCWP_D011 Diabetes Formulation

SR BCWP_E003 Psychostimulant FormulationSR BCWP_E004 BPH Preclinical

Prodrug BCWP_P001 Anti-cancer PreclinicalLiposome BCWP_Y001 Anti-cancer Formulation

CONTACT US

David Kim, DirectorOverseas Business Department• Phone : +82-2-2182-0466• E-Mail : tree365@bcwp.co.kr• Head Office : 78 Gaepo-ro 22gil

Gangnam-gu, Seoul, Korea

Myung-Kwan Chun, PhD., DirectorResearch Planning Team• Phone : +82-31-628-0921• E-Mail : chunmk@bcwp.co.kr• GRI : A-3, Korea Bio Park,

694-1 Sampyeong-dong, Bundang-gu, Seongnam-si, Gyeonggi-do, Korea

· Company BCWORLD PHARM. CO., LTD.· CEO Steve H. Hong· Specialty · DDS-oriented Pharmaceutical Company

· Therapeutic categories such as pain, anesthesiology, neurology, and musculoskeletal diseases

· Location 78 Gaepo-ro 22gil Gangnam-gu, Seoul, Korea· Homepage www.bcwp.co.kr

CILACIN INJ.

MEROGEL

PAMIRON INJ.

Towards Global Standard R&D for Healthcare Products

BCWORLD PHARM. CO., LTD.

Pharmaceutical

Pharmaceutical

98

CONTACT US

Joo-Sung Yang, Ph.D., Head of New Drug R&D Center• Phone : +82-42-930-8670• E-Mail : jsyang@bioneer.com

· Company BIONEER CORPORATION· CEO Han-Oh Park, Ph.D. · Specialty Molecular Diagnostic, Genomic New Drug, Genomic Science,

Synthetic Vaccine· Location 49-3, Munpyeong-dong, Daedeok-gu, Daejeon 306-220, Korea· Homepage www.bioneer.com

Bioneer, an innovative biotech company since 1992

Leadership in RNAi Therapeutics:Bioneer Corporation is Korea’s leading biotech company. Bioneer was the first Korean biotechnology company when it was established in 1992. The company has developed state of art molecular biology products and technologies including oligonucleotides/siRNA and instruments of gene manipulation. The company is positioned to fully-integrate its capability to develop next generation technologies in the post-genome era through the invention of new biochemistry and instruments. By capitalizing on the foundational technologies and products developed over 10 years, Bioneer has developed a solid vertically integrated infrastructure to support new higher value-added businesses such as novel RNAi drug development and molecular diagnostics.

Bioneer’s siRNA Drug Development Program using SAMiRNATM TechnologySAMiRNA (Self-Assembled-Micelle-inhibitory-RNA) is a novel class of RNAi molecule, developed by Bioneer, which allows efficient and safe in vivo delivery of siRNA to target tissues. SAMiRNA is a SCE (single Chemical Entity), which is manufactured using a proprietary process that greatly simplifies the manufacture and QC process relative to other state-of-the-art RNAi delivery platforms. SAMiRNA overcomes major challenges for safe and effective siRNA delivery as well as adverse effects of delivery vehicle. Other advantages of SAMiRNA include its flexibility to incorporate siRNA sequences against any disease target, as well as enhancement of its therapeutic potential as a delivery platform through the use of cell-type specific targeting ligands. These features and pre-clinical research data suggest that SAMiRNA is the most unique and singularly effective RNAi prodrug system developed to date.

Vertically integrated processes within Bioneer’s siRNA Drug Development Program provide a total solution for siRNA therapeutics discovery and development, from siRNA design/synthesis and preclinical tests to IND filing. With its world’s-best RNAi core technologies and manufacturing infrastructure, Bioneer is the ideal partner for pharmaceutical and biotechnology companies currently working on the development of RNAi therapeutics, or seeking to enter the RNAi field. Bioneer’s research and technical support teams ensure top-quality products and services to meet your unique needs.

R&D PipelineBioneer is currently advancing clinical development of pipeline programs for previously non-druggable targets, including cancer, IPF/COPD, liver fibrosis, and antivirals, internally with our research and development resources as well as through partnerships with major global pharmaceutical companies.

Programs Discovery Development Preclinical Clinical TrialsPhase I Phase II Phase III

BIONEER PROGRAMSSolid Cancers(SAMiRNA-Survivin)

IPF/COPDLiver FibrosisAntivirals

PARTNER PROGRAM Liver CancerSANOFI

A Leading Biotech Company

BIONEER CORPORATION

Pharmaceutical

Pharmaceutical

98

Boryung Pharmaceutical company (here after Boryung), since founded in 1963, has been trying its best to contribute to the health and well-being of humanity with corporate mission to ‘realize mutual health and co-prosperity based on human centered values’. Boryung has invested continually on research and development and made continuous efforts to produce high-quality products in the specialty areas such as cardiovascular, antineoplastic and antibiotics drugs. As a result, our products such as Gelfos M, Yongkaksan and Kyushin have become the best selling products and Boryung has emerged as the most familiar and trusted brand in Korea.

Products

Kanarb® (Fimasartan)Boryung has developed Kanarb® by our proprietary technology. Kanarb is an innovative anti-hypertensive drug that has been approved by the KFDA as the 15th new drug in 2011, also it is 8th new ARB in the world. It was also awarded with ‘Korea Technology Awards’ by the Ministry of Knowledge Economy and ‘Oh Song New Drug Prize’ by the KFDA in 2011. Kanarb is the best selling ARB in Korea and has USD 30 million sales in 2014. Until now, Boryung has successfully licensed-out Kanarb® with Mexico and 12 other Latin countries, Brazil, Russia and China and launched in Mexico September of last year. Also we are under business licensing discussions with Japan, USA, Europe, Australia etc.

Kanarb Combination drugsBoryung has been developing Kanarb combination drugs (BKC002, BKC003, BKC004, BKC007) for more severe patients who are suffering from hypertension, hyperlipidemia, heart failure and diabetes mellitus. For these combination drugs, we are under business licensing discussions with Kanarb® licensed-out companies and seeking potential partners for oversea markets.

R&D PipelineCategory Therapeutic area Indication Product RS PC PI PII PIII RG Launch

IMDCV

Hypertension BKC 001 ○

Hypertension BKC 002 ○

Hypertension Hyperlipidemia BKC 003 ○

Hypertension Hyperlipidemia BKC 004 ○

Hypertension Hyperlipidemia BKC 007 ○

CNS Alzheimer's disease BNT 002 ○

Biologics

Vaccine BVN 001 ○

Vaccine BVN 002 ○

Vaccine BVN 003 ○

Liver cancer BCB 002 ○

Contact Information

Ji Hyun MinR&D stratergic planning• Phone : +82-2-740-4019• E-mail : minjyun@boryung.co.kr

· Company Boryung Pharmaceuticals co., Ltd.· CEO Tae Hong, Choi· Specialty Full ingredient Pharmaceutical product and substance· Head Office 136, Changgyeonggung-ro, Chongro-ku, Seoul· Homepage www.boryung.co.kr

Molecular Structure

60mg fimasartan

120mg fimasartan

Total Healthcare Company Contributing to the Human Health

Boryung Pharmaceutical co., Ltd.

Pharmaceutical

Pharmaceutical

1110

To Contribute to Society through Supplying Value-added New Products to Help Patients Suffering from disease

Bukwang Pharmaceutical Co., Ltd.

CONTACT US

Choi, In AeProduct Development• Phone : +82-2-8288-078 • E-mail : iychoi@bukwang.co.kr

Bukwang Pharmaceutical Co., Ltd. is one of the innovative pharmaceutical companies in Korea and was founded in 1960 with dedication to development and commercialization of novel, outstanding medicines. Bukwang has successfully achieved remarkable growth for over fifty years. Now Bukwang has 520 employees or so, with over 180 billion Korean won of net sales in fiscal year 2010.

Through many years of effort, ‘Levovir® cap. (clevudine)’, the 4th drug worldwide for hepatitis B virus, was finally approved by KFDA in 2006, and it is the 11th New Drug developed in Korea. Levovir® was licensed out to Eisai, a Japanese company, and they paid 44 million dollars for the license of clevudine in Asian countries including China.

Bukwang reinvests a part of its profit for continual development of new products. Several projects for developing new medicines are ongoing in the R&D center.

Bukwang will use its novel tools and technologies to attain a prominent market position in the pharmaceutical industry field, increasing its business profitability and the value of the company while providing effective new solutions to incurable diseases and fundamental biological processes.

Products

Levovir® cap.(clevudine) : an innovative new drug for chronic hepatitis B virus)

Levovir was developed by Bukwang and it is the 4th drug developed for HBV infection worldwide, and the 11th new drug in Korea. It is potent in suppression of hepatitis B virus and it has excellent safety and tolerability profiles.

R&D Pipeline

Targeted anti-cancer agent (apatinib mesylate)

- Phase III clinical trial for colorectal cancer and lung cancer completed in China- Phase I/II approved in USA as well as in Korea

Antivirus drug for hepatitis B virus

- Combination drug of clevudine and adefovir dipivoxil to maximize the effectiveness of treatment and to inhibit resistant virus reciprocally- New drug: gained development right for prodrug and exclusive sales rights worldwide from Georgia University, USA.

Novel antivirus drug for Herpes Zoster

- License agreement of a new substance called “L-BHDU”- New synthetic substance collaborated by Georgia and Yale University, USA

Diabetic neuropathy drug

- New drug using only a stereoisomer of thioctic acid- Completed phase III trial

· Company Bukwang Pharmaceutical Co., Ltd.· CEO Lee, Sung Koo· Specialty Pharmaceuticals and sanitary aids· Location 398-1, Daebang-dong, Dongjak-gu, Seoul, Korea · Homepage http://www.bukwang.co.kr

Levovir

Pharmaceutical

Pharmaceutical

1110

Celltrion's goal is to provide affordable alternatives to the high-priced antibody drugs, price of which limits broad usage of the drugs. Celltrion prides itself in being the first company in the world to apply for global regulatory approval of an antibody biosimilar. We are using our accumulated R&D technology and manufacturing capabilities to develop, manufacture and market antibody biosimilars and innovative drugs to patients in need. Celltrion hopes that more suffering patients will be able to have access to and benefit from the new availability of advanced biomedicines.

Products Remsima™ (infliximab) is the world’s first biosimilar mAb to receive positive opinion from an advanced and developed nations’ regulatory body, which is a monoclonal antibody against tumor necrosis factor alpha (TNF-α) used to treat autoimmune diseases like ankylosing spondylitis, rheumatoid arthritis, Crohn’s Disease, ulcerative colitis, psoriasis and psoriatic arthritis. The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) had given positive opinion for Celltrion-developed Remsima™ for sale in the European Union (EU) in June 2013. With this positive CHMP opinion, Celltrion is permitted to obtain marketing authorization approval (MAA) from 27 EU countries and 3 EEA (European Economic Area) countries (for a total of 30 countries) through simple administrative procedures. Remsima has already received approval from the MFDS (former KFDA) in July, 2012. Global launch of Remsima™ is remarkably good news for patients who previously had limited access to advanced therapeutics, in particular, those hindered by the high cost of antibody biopharmaceuticals. We believe that the first biosimilar mAb approval by the EMA will spearhead the start of a new era of biosimilar mAbs in the pharmaceutical industry. Celltrion, Inc. also has gained entry into the $24 billion TNF-α antagonist market and is likely to be the only biosimilar product in the market for the next 4 to 5 years.

R&D Pipeline Celltrion currently has 8 biosimilars candidates in various stages of development. The CT-P6 (Breast Cancer) Project is in their most advanced stages of development, successful completion of clinical trials conducted in over twenty countries and completed submission for approval in Korea.

PROJECT CT-P06 - Indication: Metastatic and early breast cancer that over express HER2 gene (Protein Type: mAb)

PROJECT CT-P10 - Indication: Rheumatoid arthritis, Non-Hodgkin’s lymphoma (Protein Type: mAb)

As a company specialized in antibody drug development, Celltrion is also developing innovative antibody drug (PROJECT CT-P27) to overcome the limitations of existing vaccines and synthetic drugs for pandemic or seasonal influenza viruses. Celltrion received IND approval from England’s Medicines and Healthcare products Regulatory Agency (MHRA) to initiate a phase 1 clinical trial for CT-P27, an influenza antibody shown to have efficacy for pandemic and seasonal flu strains, including various subtypes of influenza viruses. The results of animal tests conducted by the US Center for Disease Control and Prevention showed that this new antibody drug may be effective in treating avian influenza, influenza A and many other variationsof influenza viruses. Thus, this new drug is expected to become the world’s first comprehensive influenza virus treatment antibody, if succeeded. Additionally, Celltrion is developing innovative drug to cure rabies by collaborrating with the US Center for Disease Control and Prevention. Celltrion is also working with a US biotech company to develop an antibody drug that is expected to be a cure for breast cancer and lung cancer. Other than the antibody drugs pipeline, Celltrion is focusing on developing antibody-drug conjugate that minimizes side effects and maximizes efficacy by integrating antibodies with synthetic drug substances. Celltrion’s broad innovative drug pipeline is expected to serve as the driving force behind Celltrion’s future growth.

CONTACT US

Celltrion Headquarters• Phone : +82-32-850-5008• Fax : +82-32-850-5057• E-mail Business : contact@celltrion.com Investment : investor@celltrion.com Career : recruit@celltrion.com

· Company Celltrion, Inc.· CEO JungJin Seo· Specialty biopharmaceutical development and manufacture · Head Office 13-6, Songdo-dong, Yeonsu-gu, Incheon, 406-840, South Korea· Homepage www.celltrion.com

A Global Technology Leader in the Field of Biosimilar and Biologic Drug Development

Celltrion, Inc.

Remsima™

Pharmaceutical

Pharmaceutical

1312

CONTACT US

Indy Baik, DirectorGlobal Business Team• Phone : +82-2-3149-7849• E-Mail : ihbaik@ckdpharm.com

Chong Kun Dang Pharmaceutical Corp. (CKD) was established with the objective of supplying the best quality medicine to the people who need them and performing its business activities for the development of pharmaceutical industry in Korea for over 70 years since its inception in May 1941.

Products In 1968, CKD obtained US FDA approval for Chloramphenicol, Chloramphenicol palmitate and sterile Chloramphenicol sodium succinate. It was the first commemorative US FDA approval for raw materials in Korean pharmaceutical industry. In addition, CKD has gained additional US FDA approvals for raw materials such as Oxytetracycline hydrochloride, Tetracycline, Rifampicin, Demeclocycline and so on.Since exporting antibiotics to Japan in 1969, CKD has acted as a pioneer of Korean pharmaceutical companies by entering more than 40 overseas markets with the finished products such as Rifampicin, anti-tuberculosis drug.In R&D, CKD was the first company to establish a Research Institute in 1972 among Korean pharmaceutical companies. Through continuous research, CKD had succeeded in the development of many specialty products such as Cipol N®(ciclosporin) and TacroBell®(tacrolimus), immunosuppressive agents for organ transplantations. Such successful developments brought CKD a variety of awards such as Korea Technology Mark and Technology Research Institute Prize.In 2008, CKD’s Lipilou®(atorvastatin), a treatment for high cholesterol was awarded as Korea Technology Gold Prize, and its new formulation and process improvement of atorvastatin were evaluated as Korea’s 10 New Technologies.

R&D PipelineCKD has been focusing on research and development of New Chemical Entities(NCE), Incrementally Modified Drugs(IMDs) and Bio-pharmaceuticals.In the field of NCEs, Camtobell® was launched in 2004, as the first CKD new drug developed by its own technology. Based on this successful experience, Duvie® which is a thiazolidinedion derivative for type 2 diabetes has been approved by Ministry of Food and Drug Safety(MFDS) in 2013 and launched on February 1st of 2014. CKD-732 (beloranib) developed by CKD has been licensed out to Zafgen. Currently, CKD-732 is under development for treatment of severe obesity and its phase IIb clinical trial for treating obese subjects with Type 2 diabetes has been in progress in the US and Australia. Furthermore, CKD-732 showed positive efficacy on Prader-Willi Syndrome and has been designated as an orphan drug by FDA & EMA. It is under phase III clinical trial in the US.CKD-516 (Vascular Disrupting Agent) and CKD-581 (Pan-HDAC inhibitor) are drug candidates for the treatment of solid and hematological cancers and are undergoing Phase I clinical trials. In addition, CKD-519 is a CETP inhibitor, which increases HDL cholesterol, being developed for dyslipidemia and is in phase I clinical trial. In case of IMDs, CKD is focusing on the development of combination products and DDS for a new type of oral antibiotics and nanoparticles with the skilled infrastructure.As of Bio-pharmaceuticals, CKD-11101, anti-anemia agent, is a biosimilar of NESP® and it successfully completed phase I clinical trial. Multicenter Phase III clinical trial has been recently conducted to compare the efficacy and safety of the reference product. CKD-12201, prophylactic HPV vaccine for cervical cancer prevention, has successfully completed phase I clinical trial.

· Company Chong Kun Dang Pharmaceutical Corp.· President & CEO Young-Joo Kim· Specialty R&D of new medicine and incrementally modified drug (IMD)· Location 8, Chungjeong-ro, Seodaemun-gu, Seoul, Korea· Homepage www.ckdpharm.com

Lipilou tab., anti-hyperlipidemic agent

Camtobell inj., anti-cancer agent

Duvie® Tab. Anti-Diabetic agent

BINT Medicine R&D Corporation for Terminal Illnesses(BINT: Bio-Info-Nano Technology)

Chong Kun Dang Pharmaceutical Corp.

Pharmaceutical

Pharmaceutical

1312

· Company CJ HealthCare corporation· CEO Dal won Kwak, Chul ha Kim· Specialty Business

ETC (CVs, Antibiotics, IV Solution, Oncology, Endocrinology, Nephrology&Urology, Gastro Intestinal, Musculo skeletal, Respiratory, Others) & Health functional products

· Head Office CJ CheilJedang Center, 330, Dongho-ro, Jung-gu, Seoul 100-400, Korea· Homepage www.cjp.co.kr

Big leap to global pharmaceutical company

CJ HealthCare Corp.

Heal the World, Better LifeCJ HealthCareCJ HealthCare started its business as Pharmaceuticals Business Unit at CJ CheilJedang Corporation from 1984. In line with CJ's corporate vision, CJ HealthCare has been striving for making people healthier, happier and better convenient with innovative and differentiated pharmaceutical products. As of 1st April, 2014, CJ HealthCare was spun off from CJ CheilJedang Corporation and became a separate pharmaceutical corporate entity with purpose of enhancement of expertise in pharmaceutical business to grow globally. CJ HealthCare has become a representative Korean pharmaceutical company in promising therapeutic areas such as oncology, cardiology, endocrinology and nephrology. CJ HealthCare is working hard to grow globally, focusing on rapidly growing China and Southeast Asian markets as well as highly-regulated but attractive Japan and EU markets. Through our newly established cGMP compliant plant in Osong, CJ HealthCare can secure global standard manufacturing facilities and operation capabilities.CJ HealthCare will make its best efforts to jump into a leading position among global pharmaceutical companies.

Products

R&D Pipeline구분 Pipeline Description DS PC PI PII PIII NDA MKT Licensed

TerritoryMolecule Target Indication

NCE

NEPA UNDISCLOSED antiemetics Korea

CJ-12420 UNDISCLOSED Gastric Acid-Related Disorders

KoreaChina

taiwan

IBAT Inhibitor UNDISCLOSED Gastric Acid-Related Disorders

JAK Inhibitor UNDISCLOSED arthritisPhyto-pharma. CJ-20001 UNDISCLOSED Gastritis

IMD

CJ-30056 Atrovastatin, Metformin

Type 2 Diabetes/Hyperlipidemia (FDC)

CJ-30041 Pemetrexed Soln.

Hypertension/Hyperlipidemia

CJ-30059 Candesartan, Amlodipine Hypertension (FDC)

CJ-30060 Atrovastatin, Metformin

Type 2 Diabetes/Hyperlipidemia (FDC)

CJ-30061 Bisoprolol, Atrovastatin

Hypertension/Hyperlipidemia (FDC)

Biologicals

CJ-40001 Darbepoetin AnemiaHand-Foot-Mouth Disease vaccine UNDISCLOSED Hand-Foot-Mouth

DiseaseLUCENTIS Biosimilar UNDISCLOSED Retinopathy

CJ HealthCare, Korea(Headquarters)CJ CheilJedang Center, 330, Dongho-ro, Jung-gu, Seoul 100-400, Korea • Tel: +82-2-6740-2181• FAX: +82-2-6740-2491• E-mail: khong@cj.net

(Kwang Hee Hong, PhD, MBA)

CJ Europe GmbHOber der Roeth 465824 Schwalbach, Germany• TEL: +49-6196-590128 • FAX: +49-6196-45418• E-MAIL: hosanna@cj.net

(Youngsun Lee)

CJ Japan Corp.8F, CJ Bldg, 2-7-4, Nishishinbashi, Minato-ku, Tokyo, 105-0003, Japan• TEL: +81-3-3519-3452• FAX: +81-3-3580-1055• E-MAIL: bean@cj.net (Sungbin Cho)

China branch office北京市朝阳区酒仙桥路20号颐堤港一座12层 P.C 100016• TEL: +86 -10 - 5639 – 6053• E-MAIL: leesj337@cj.net (Sangjae Lee)

Vietnam branch officeS18, 22F, STC Bldg, 37 TonDuc Thang st. Dist.1, HCMC, Vietnam• TEL: 84-8-3911-0458• E-MAIL: kuminki@cj.net (Minki Ku)

Contact Information

Product Details1. Epokine Inj. (rh-EPO) Epokine® was developed 1st in Korea and 3rd in the world. Epokine® is safe and effective in treating

anemia of hemodialysis patients with end-stage renal disease.

2. Leukokine Inj. (rh- G-CSF) Chemotherapy in advanced cancer patients and in acute Leukemia patients can cause the Neutropenia. Leukokine® can help to support their natural defenses during strong chemotherapy.

3. Vancorin Inj. (Vancomycin) Vancorin® is the best choice for MRSA & MRSE.4. Tapocin Inj. (Teicoplanin) Tapocin® has excellent antibacterial effects on MRSA, MRSE and Enterococcus.5. Moveloxin I.V. solution bag(Moxifloxacin)

As a fourth-generation synthetic fluoroquinolone antibacterial agent, Moveloxin® I.V. solution bag is convenient to use for doctors and nurses in hospitals.

6. Cinezolid I.V. solution bag(Linezolid)

As the treatment of vancomycin-resistant Enterococcus faecium infections, Cinezolid® I.V. solution bag is convenient to use for doctors and nurses in hospitals.

7. Calmtop Inj. (Irinotecan) Calmtop® Inj. is an injectable drug used for the treatment of colorectal cancer

8. Pemta Inj. (Pemetrexed) PEMTA® Inj. is a chemotherapy RTU (ready-to-use) injectable drug for the treatment of pleural esothelioma and non-small cell lung cancer.

9. CONDITION (Hangover relief drink) CONDITION® has launched in 1992 creating a new market of hangover relief drink in Korea.

10. HongSamJin Gold (Red Ginseng drink) HongSamJin Gold® is an outstanding energy drink produced with 6-yeared red ginseng.

11. HutGaeSoo(Thirst –quenching tea drink) HutGaeSoo® contains the goodness of Hovenia dulcis with its function of liver protection.

Pharmaceutical

Pharmaceutical

1514

CONTACT US

Steven Kim, R.Ph., MBA,Director, Business Development• Phone : +82-31-628-2720• E-mail : skim@cgxinc.com

· Company CrystalGenomics, Inc.· CEO Joong Myung Cho, Ph.D.· Specialty Business Discovery and Development of Novel Therapeutics· Head Office 5th F., A Tower, Korea Bio Park, 700 Daewangpangyo-ro, Bundang-gu,

Seongnam-si Gyeonggi-do, 463-400 Korea· Homepage www.crystalgenomics.com

Clinical Stage Biotech Company with Robust Pipeline and Proven Track Record in Discovery and Development of Novel Drugs

CrystalGenomics, Inc.

CrystalGenomics, Inc. is a clinical stage biopharmaceutical company that is dedicated to the discovery and development of novel pharmaceuticals with innovative platform technologies to address significant unmet medical needs in the areas of infectious disease, oncology and inflammatory diseases. The Company is headquartered in Korea and has a US subsidiary company in California for the management of multi-national clinical studies, and it is publicly traded on the KOSDAQ exchange.CrystalGenomics is developing several drug candidates for various therapeutic areas in different development stages. Its lead drug program is Acelex® (polmacoxib), a next generation NSAID for osteoarthritis. The NDA has been recently approved by the MFDS (Korean FDA). The second clinical stage program is CG400549, a first-in-class antibiotic for MRSA where its phase 2a skin infection study in the US was recently completed with a positive outcome of 100% clinical cure rate. The third clinical stage program is CG200745, a molecular targeted anti-cancer therapeutic for various types of cancers, which is in phase 1b/2 ready stage. In addition to the aforementioned programs, CrystalGenomics has several other drug programs in preclinical and discovery stages.

Products· Polmacoxib (Next Generation NSAID for Osteoarthritis) DRUG TARGET: Dual Cyclooxygenase-2 and Carbonic Anhydrase Inhibitor INDICATION: Osteoarthritis STATUS: Approved - Polmacoxib is a novel NSAID with unique mode of action being developed for the relief of signs and symptoms of

osteoarthritis. After successful completion of a Phase 2a Proof-of-Concept study in Europe with 248 patients, a Phase 2b active-controlled efficacy study in Korea against Celebrex, and a Phase 3 active-controlled pivotal study has been completed. The Korean NDA has been approved by the MFDS (Korean FDA) over 9 clinical studies in various parts of the world, and more than several hundred patients have been dosed on polmacoxib. Based on the cumulative clinical data, polmacoxib is projected to have an excellent safety and efficacy profile.

· CG400549 (Potentially First-in-Class Fab I Inhibitor for MRSA) DRUG TARGET: Fab I inhibitor (enoyl-[acyl-carrier-protein] (ACP) reductase) INDICATION: ABSSSI, Osteomyelitis, Other serious infections associated with Staph aureus. STATUS: Phase 2a completed - CG400549 is a novel antibiotic candidate for MRSA and recently obtained human POC from the completed Phase

2a Study in the US. Both Phase 1 Single Ascending Dose and Phase 1 Multiple Ascending Dose studies have been completed in the EU.

- CG400549 is a novel antibacterial drug candidate that inhibits enoyl-[acyl-carrier-protein] (ACP) reductase (fabI), an essential enzyme in fatty acid synthesis. Since fatty acids are an ingredient of bacterial cell walls, its synthesis is critical for the survival of bacteria.

- From the phase 2a POC study, 90.9% of evaluable subjects had early clinical response at the ECE visit (48 to 72 hours after enrollment or Day 3~4) and 100% of evaluable subjects were clinically cured by the TOC visit (Day 21~28)

· CG200745 (Potentially Best-in-Class HDAC Inhibitor for Solid Tumors) DRUG TARGET: HDAC inhibitor INDICATION: Various Solid Tumors and Hematologic Cancers (Pancreatic Cancer, Hepatocellular Carcinoma, Colorectal Cancer, MDS, etc.)

STATUS: Phase 1 completed, Phase 1b/2 being prepared for pancreatic cancer and MDS - CG200745 is an anti-cancer agent that deactivates HDAC, an enzyme that catalyzes the histone deacetylation. CG200745

shows a better profile when compared to other compounds in the same class such as Zolinza® of Merck & Co. (approved), based on a series of anti-cancer efficacy tests using various cancer cell lines and xenograft animal models.

- In addition to superb efficacy and safety demonstrated so far, CG200745 has shown excellent PK and PD profiles and there is a good probability that it can be developed for a variety of solid tumor indications including pancreatic, colorectal, and liver cancer.

R&D PipelineArea Candidate Indication NCE Type Ph I Ph IIa/IIb Ph III Registration

Inflammation Polmacoxib Osteoarthritis FIC1

Infectious Disease CG400549 ABSSSI, MRSA FIC, BIC2

Oncology CG200745 Various solid & liquid tumors BIC2

1 First-in-Class; 2 Best-in-Class

Pharmaceutical

Pharmaceutical

1514

CONTACT US

Overseas Business• Hanwonng, Seo Tel: 82-2-6716-1071 e-mail: shw0817@dhpharm.co.kr• Paul, Cho Tel: 82-2-6716-1072 e-mail: crispaul@dhpharm.co.kr

DAE HWA has developed all kinds of medicines ranging from peptic ulcer medicines to preventive and assistant treatments including a cancer, adult related disease, etc. DAE HWA was established in 1984 with the vision of pursuing the happiness of mankind. With the completion of the cGMP facilities in 2009, we are striving to produce high quality medicines.

Currently, we are producing 150 kinds of medicine and supplying to around 3,000 hospitals nationally as well as conducting business with around 6,000 pharmacies.

Our lipids-based oral formulation technology is an outstanding global leading technology. DHP107, an oral paclitaxel formula, is mainly composed of edible oils and does not need co-administration of an absorption enhancer or efflux pump inhibitor.

Ongoing phase 3 clinical trial will be completed soon and DAE HWA is expecting first approval of oral paclitaxel form in the world. Also, we have plan for worldwide clinical development and commercialization with a collaboration or partnership.

DAE HWA is continuing our research on transdermal drug delivery system (TDDS) technology. Moreover, we are developing a new platform technology for Orally Disintegration Film (ODF) products. Also, DAE HWA is focusing on the developing of innovative herbal products both as medicines and functional foods for cardiovascular, neurological area.

As well as the release of Kebanon, Loxona, Plocfen, Hyemingo, DDL (NSAIDs medication), Resnalin (asthma medications, 2010), Duphenyl (narcotic analgesics, 2014) and Rivamensa (dementia medication, 2014), we are understudying to release reformulated NSAIDs, incontinence medicines, antihistamine medications, antidepressants, antivirus medicine, CSN medication etc. using TDDS/ODF technology and developing new herbal medicine & functional food for Alzheimer’s and Parkinson’s disease.

Global BusinessDAE HWA has been exporting to Asia, South America, Africa and Middle East. And at now, DAE HWA has trading relationship with 22 countries in the world.

For the newly developed European market, DAE HWA launched anti-inflammatory analgesic plaster and cataplasma from France and Bulgaria as center. And for the US market which started exporting since end of 2012, and DAE HWA will gradually increase exporting products in the US market through the continued R&D, market research and localization.

And in case of China which also has huge market, DAE HWA already entered into supplying and distribution agreement for 4 products.

· Company Dae Hwa Pharmaceutical Co. Ltd.· CEO Han Koo, Lee & Soo Ji, Kim· Specialty Medicinal Products· Location (Seoul Office) 2038 DaeHwa Bldg., Nambusunhwan-ro, Gwanak-gu, Seoul, Korea· Homepage www.dhpharm.co.kr

Respecting Life & Serving Society

Dae Hwa Pharmaceutical Co. Ltd.

Rivamensa Patch

Loxona Cataplasma

DDL Plaster

Top-Roll soft cap.

Resnalin patch

Kebanon plaster

Regulatory Affair• Claire, Kim Tel: 82-2-6716-1073 e-mail: dhkim@dhpharm.co.kr

Pharmaceutical

Pharmaceutical

1716

CONTACT US

SinHo Choi• Phone : +82-2-2204-6975• E-mail : shchoi01@daewonpharm.com

Andy Lee• Phone : +82-2-2204-6971• E-mail : ehlee@daewonpharm.com

Be a partner who protects healthy life of human beings based on reliability and trust of customers.Since the establishment in 1958 with a founding idea of “realization of human health.”, Daewon Pharm. Co., Ltd. Has made the best efforts for human health and happiness through manufacturing and providing specialized medicines. We produce reliable and safe medicines by securing world-class manufacturing facilities and superior R&D capabilities.

Daewon pharm produces both vitamins to improve human health and other specialized medicine for circulatory, respiratory, antibiotic, chemotherapy and psychoneurosis uses. You can find information about our products on our homepage(www.daewonpharm.com). Please visit our website for the details.

With its first export to Vietnam in 1994, Daewon Pharm has made eye-opening achievements of exports. Now, We export our products to 40 countries such as China, Latin America, Middle East, CIS, and Africa. Daewon is exporting about 50 products and is expanding its export volume with products such as Pelubi tablet, a new chemical entity, and Oramin Capsule, multivitamin supplement with Korean Ginseng.

ProductsOramin Capsule

World’s favorite multivitamin, Oramin Cap., by Daewon contains high quality Korean Ginseng and royal jelly as well as all sorts of vitamin and minerals necessary for vital daily life. Oramin, Our representative global brand, demonstrates the superiority of Korean ginseng all over the world, being ranked first out of multivitamin brands in 4 countries.

Pelubi tablet(the 12th new medicine in Korea)

The Pelubi tablet, a series of NSAIDs, was developed in the whole process from raw materials to end product only by Daewon Pharm and Certificated as the 12th new medicine by Korean Food and Drug Administration. It is a highly effective NSAIDs for pain relief which has less side effects than existing NSAIDs products.

R&D Pipeline

Tech. Type Project Indication StageNCE DW10558 Hypercholesterolemia Pre-clinical

NCE + Sustained Release DW0908 NSAIDs Application submitted

Natural Extract + Sustained Release DW1401 Gastritis Phase Ⅲ

Sustained releaseDW1030 Antispasmodic Application submitted

DW8486 Epilepsy Phase Ⅰ

CombinationDW340 NSAID + Antispasmodic Phase Ⅰ

DW0929 Hypercholesterolemia Phase Ⅲ

· Company Daewon Pharmaceutical Co., Ltd.· CEO Baek, Seung Ho / Baek, Seung Ryel· Specialty Drug manufacture and sales· Location 229-3 Yongdap Dong, Sungdong-Gu, Seoul, Korea· Homepage www.daewonpharm.com

Oramin Capsule

Pelubi tablet

Reliable Partner for Human Health

Daewon Pharmaceutical Co., Ltd.

Pharmaceutical

Pharmaceutical

1716

CONTACT US

Global Business Development and License Out• Mr. Doyoung (Brian) Kim, Senior

Manager, Global Strategy Dept.• Phone : +82-2-550-8936• E-Mail : doyoung.kim@daewoong.co.kr

Early Stage Collaboration and License In/Out• Ms. Alice Lee, Manager Connect & Development • Phone : +82-31-270-8328• E-Mail : alice@daewoong.co.kr

Daewoong Pharmaceutical is the pharmaceutical company with the No. 1 sales of prescription drugs in the Korean market.Established in 1945 in Seoul, South Korea, Daewoong Pharmaceutical offers high-quality and innovative pharmaceutical products and is one of the top market leaders in Korea.For over 60 years, Daewoong Pharmaceutical has been providing better health for people through its total dedication to healthcare. Daewoong has built strong core competency for new drug development to meet diverse medical needs and enhance human life.Building on our core strength, Daewoong Pharmaceutical has involved in becoming a global healthcare group by operating our foreign branches in SE Asia and by collaborating with global partners. We have an inspiring mission to become a top 50 global healthcare company which contributes to improving the quality of life for people worldwide.

The reinforcement of the R&D capacities through the establishment of R&D center in the USA, China and India.Daewoong Lifescience Research Institute has been focused on developing new chemical entities, biologics, incrementally modified drugs and high-value added APIs. Daewoong has also been studying to find solutions for the unmet therapeutic needs of neuropathic pain disease, Alzheimer’s disease as well as other innovative programs like anticancer gene therapy. Daewoong is operating several overseas offices in China, Vietnam, Indonesia, Thailand, Philippines, USA, and India and has R&D centers in China, India and America.

R&D PipelineNew Chemical Entities

Code type indication Development StatusR Pre PI PII PIII M

DWJ205 Fungicidal Oral fungicidal program ○DW206 APA (Acid Pump Antagonist) Antiulcer program ○DWJ208 Ion channel blocker Neuropathic pain, Cancer pain ○DW209 PRS inhibitor Lung cancer, pancreatic cancer ○

Biologics

Brand MOA Description Development StatusR Pre PI PII PIII M

Novosis BMP-2Dental sinus lifting graft ○

Spinal fusion device ○

Easyef EGFDiabetic foot ulcer, spray type ○

Oral mucositis, spray type ○Acute wound healing (OTC) ○

Caretropin hGHLyophilized powder ○

Pen type injector + Liquid Cartridge ○Eposis EPO Biosimilar, Recombinant Human Erythropoietin ○

Nabota Botulinum toxin type AGlabellar lines ○

Upper Limb Spasticity ○

Value-added Generics & Generics

Brand MOA Description Development StatusR Pre PI PII PIII M

Olostar Olmesartan + Rosuvastatin fixed dose combination ○URSA Ursodeoxycholic acid 250/300/500mg Tablets ○Albis Ranitidine + Bismuth + Sucralfate fixed dose combination ○

Dihecta Dioctahedral smectite suspension ○Luphere Leuprolide PLGA polymer encapsulated depot ○Neovest Iopromide X-ray contrast agent ○Nurigra Sildenafil tablet ○

Nurigra Chew Sildenafil chewable tablet formulation ○Imatinib Imatinib Generic of Glibec (100mg: BE, 400mg P1) ○

· Company Daewoong Pharmaceutical Co., Ltd.· CEO Lee, Jong Wook· Specialty small-molecule new drugs, biological drugs, value-added chemical drugs· Head Office 163-3, Samsung-dong, Kangnam-gu, Seoul, Korea· Homepage www.daewoong.com

Pharmaceutical Company with the No.1 Sales of Prescription Drugs in Korea

Daewoong Pharmaceutical Co., Ltd.

Pharmaceutical

Pharmaceutical

1918

CONTACT US

• Phone : +82-2-2191-9859• Fax : +82-6234-0589• E-Mail : kjh2@dkpharm.co.kr

Dongkook Pharmaceutical is marching into the world with global competitiveness.

For the past 44 years, Dongkook Pharmaceutical has made continuous efforts to uphold respect for life and healthy national lives on the basis of corporate philosophy of creativity, harmony and credibility.Since the company was listed on the KOSDAQ in May 2007, Dongkook Pharmaceutical’s strong R&D capabilities and corporate values have been widely recognized. Today, Dongkook Pharmaceutical is being reborn as a global enterprise that has proven its potential power to the whole world.

Dongkook Pharmaceutical has also been well recognized in and outside Korea with the superiority of the products and the competitive product portfolio in the field of prescription medicines. Dongkook Pharmaceutical has developed and produced outstanding therapeutic products through various clinical trials.

In 2006, Plant 2 acquired a rating of Grade A, the highest grade, in the injection sector from the GMP (Good Manufacturing Practice) assessment rating system. Plant 3 followed suit in 2008, receiving a Grade A rating during the assessment rating conducted by the government; thus proving high-level GMP management. For the first time in Korea, Dongkook Pharmaceutical met the European GMP standard in the injection sector; even in the API sector, Dongkook Pharmaceutical owns products complying with the EU Guidelines of EDQM (European Directorate for the Quality of Medicines).

Currently, Dongkook Pharmaceutical exports finished product and API to over 50 countries, especially on EU, Japan and other advanced countries with the strict regulations for pharmaceuticals. It seeks to grow into a global leading pharmaceutical company that is trusted and loved by all domestic and overseas customers backed by the greatest global competitiveness.

No. The name of Product Main Ingredient Use(Indications)1 PAMIRAY INJECTION Iopamidol X-ray contrast media for neuroradiology

2 POFOL INJECTION Propofol 10mg per 1ml Induction and maintenance of General anaesthesia

3 TEICOPLANIN INJECTION Teicoplanin Skin and soft tissue infections

4 DURAKINASE INJECTION Streptokinase Acute myocardial infarction

5 LORELIN DEPOT INJECTION Leuprorelin acetate Prostatic Cancer

R&D PipelineIn 1990, Dongkook Pharmaceutical focused on developing products through selection and concentration in specialized fields, succeeding in the development of Minocline Strip (Local Drug Delivery System), the periodontitis medicine and the manufacture of Pofol (Propofol preparation), the intravenous general anesthetic.

These two technologies were recognized as Excellent Korean Technology (KT) by the Ministry of Science and Technology in 1995 and 1996 respectively. In 2005, the company was again lauded for the superiority in formulation technologies related to long-term sustained release of peptide medicine, and it was designated as Advanced Technology Center (ATC) by the Ministry of Knowledge Economy.

Currently, the Central Research Institute’s efforts are focused on developing new products requiring creative and multidisciplinary knowledge foundation, utilizing the platform technologies of synthesis, fermentation, hydrogel, nano-emulsion, microsphere based long-acting release, and multi-particles. The development of such innovative product groups serves as a footing for expanding business areas to prescription medicine markets from over-the-counter (OTC) medicine markets and to overseas markets from domestic markets.

· Company Dongkook Pharmaceutical· CEO Lee, Young Wook; Oh, Hung joo· Specialty Pharmaceutical· Location 997-8, Daechi-2dong, Gangnam-gu, Seoul, Korea· Homepage http://www.dkpharm.co.kr/english

Human & Life

Dongkook Pharmaceutical

Pharmaceutical

Pharmaceutical

1918

GemVax & KAEL Co., Ltd. is an innovative company dedicated to development, commercialization of anti-cancer vaccine, peptide vaccine and infectious disease DNA vaccine.

Products

RIAVAX® (code name: GV1001) is the “first-in-class” therapeutic vaccine for the treatment of patients with pancreatic cancer. In September 15, 2014 Korean Ministry of Food and Drug Safety (MFDS) granted RIAVAX® a marketing and manufacturing authorization in Korea as a treatment of locally advanced or metastatic pancreatic cancer patients whose serum level is higher than 81.02pg/mL in combination with Gemcitabine/Capecitabine.RIAVAX® is a peptide vaccine derived from human telomerase that is abundantly expressed in most of human cancers. Briefly, the mechanism by which RIAVAX® kills cancer cells is to elicit combined CD4+/CD8+ T cell responses, thereby inducing tumor eradication as well as long term memory. The safety and efficacy/Immunogenicity of RIAVAX® in pancreatic cancer has been investigated and confirmed in number of previous thirteen clinical trials. In a large-scale phase lll trial TeloVac, the safety and immune-modulating effect of RIAVAX® were confirmed in over 1,000 patients. The key finding obtained from the TeloVac trial was that RIAVAX® markedly prolonged the survival in a group of patients having high serum eotaxin level (>81.02pg/mL).

R&D Pipeline

Description Indication Status

Cancer therapeutic vaccineProstate Cancer Ph lll

NSCLC(Non-Small Cell Lung Cancer) Ph llI

Peptide DrugBPH(Benign Prostate Hyperplasia) Ph ll

Alzheimer’s Disease Non-clinical

Infectious Disease DNA Vaccine

HIV(Human Immunodeficiency Virus) Ph l/ll

HPV(Human Papilloma Virus) Non-clinical

Malaria Ph l

Influenza Non-clinical

HBV(Hepatitis B Virus) Non-clinical

Vaccine Development TechnologiesPADRE (Pan-DR Epitope) -

EIS (Epitope Identification System) -

CONTACT US

Jiyeon Yoo, Deputy General Manager, Strategy & Planning • Phone: +82-2-544-6221• Fax: +82-2-3443-4997• E-mail : jiyeonyoo@kaelgemvax.com

· Company GemVax & KAEL Co., Ltd.· CEO Sang Jae Kim, Kyung Hee Kim· Specialty Developing, Manufacturing, Commercializing Biological Therapeutics· Head Office 146 Unjung-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, Korea· Homepage www.gemvax.com

GemVax & KAEL Co., Ltd. is an innovative company dedicated to development, commercialization of anti-cancer vaccine, peptide vaccine and infectious disease DNA vaccine.

GemVax & KAEL Co., Ltd.

RIAVAX

Pharmaceutical

Pharmaceutical

2120

Genexine, Inc. (KOSDAQ, 095700) is a leading biotechnology company specializing in immunotherapeutics, based on its strong immunology expertise and R&D capabilities. Founded in 1999, Genexine consists of about hundred employees, half of which are scientists with MSc or PhD. Genexine is located in Korea Bio Park, Pangyo Techno Valley near Seoul, Korea.

Platform Technology1) hyFc technology – next generation half-life extension technology: Genexine creatively invented hybrid Fc fusion half-life extension technology that enables long-acting protein therapeutics with well-balanced benefit of efficacy, safety, convenience, cost-efficiency as well as substantially low risk of immunogenicity.2) therapeutic DNA vaccine technology for infectious diseases and cancer: Through long history of DNA vaccine R&D, Genexine has accumulated extensive technology and know-how of therapeutic DNA vaccines against viruses such as HPV, HBV, TB, etc. DNA vaccine induces robust antigen-specific immune response against infected cells or cancer.

Based on proprietary innovative platform technology, Genexine has developed various products in preclinical and clinical-stages. Genexine’s major clinical pipelines are GX-H9 (long-acting hGH-hyFc) in Phase II in EU and Korea and GX-188E (therapeutic HPV DNA vaccine) in Phase II in EU and Korea. In pre-clinical stage, Genexine has GX-P2 (PD-L1-hyFc as a PD-1 agonist) for autoimmune diseases, GX-I7 (IL-7-hyFc), GX-F7 (long-acting Factor VII-hyFc), etc.

Major Pipelines1) GX-H9 (Long-acting hGH-hyFc): Long-acting human growth hormone (hGH) genetically fused with Genexine’s proprietary hybrid Fc (hyFc) platform. The first in human trial has been completed in EU and currently a multinational AGHD patient phase 2 clinical study is being conducted in EU and Korea. In phase I clinical trial, no SAEs and ADA formation were reported, and dose-dependent PK and PD (IGF-1 level) profiles were demonstrated. GX-H9 is targeting pediatric and adult growth hormone deficiency patients with weekly and semi-monthly administration and being co-developed with Handok Pharmaceuticals. 2) GX-188E (HPV therapeutic DNA vaccine): HPV therapeutic DNA vaccine for Cervical Intraepithelial Neoplasia (CIN) / Cervical Dysplasia in Phase II clinical trial. GX-188E has the potential to induce complete regression from high grade Cervical Intraepithelial Neoplasia caused by high-risk types of HPV16/18 infection. In Phase I clinical trial, Genexine demonstrated that electroporation(Ichor Medical Systems)-enhanced immunization with a rationally designed HPV DNA vaccine (GX-188E), preferentially targeting HPV antigens to dendritic cells, elicits a significant E6/E7-specific IFN-γ-producing T-cell response in all nine cervical intraepithelial neoplasia 3 (CIN3) patients. Seven out of nine patients displayed complete regression of their CIN3 lesions and viral clearance and exhibited an enhanced polyfunctional antigen-specific CD8 T-cell response within 36 weeks of follow up. These results were recently published in Nature Communications (Kim et al., Nature Comm., 2014; 5,5317).3) GX-P2 (PD-L1-hyFc as a PD-1 agonist): GX-P2 is PD-L1-hyFc as a PD-1 agonist, which is a first-in-class drug candidate in preclinical stage for autoimmune diseases. It is based on our innovative long-acting hyFc technology (next generation Fc fusion technology). GX-P2 is designed to induce T-cell tolerance by targeting PD-1 and/or B7.1 and able to regulate uncontrolled T-cell activation or proliferation in autoimmune diseases. We confirmed animal PoC in inflammatory bowel disease (IBD) and published the results in Gut journal (Song et al., Gut, 2015; 64(2):260-271).

To Improve Patient’s Quality of Life

Genexine, Inc.

CONTACT US

Business DevelopmentJaehan ParkGeneral Manager/Head of Business Development Office 1• Phone: +82-31-628-3260• E-mail : jhpark@genexine.com

· Company Genexine, Inc.· CEO Young Chul Sung, Ph.D· Specialty Hybrid Fc fusion (hyFc) proteins, DNA therapeutic vaccine· Location 700 Daewangpangyo-ro, Korea Bio Park Bldg. B, Bundang-gu, Seongnam-si, Gyeonggi-do 463-400, Republic of Korea· Homepage http://genexine.com

R&D PipelineTechnology Product Indication Concept Collaboration

Partners Discovery Pre-Clinical

ClinicalI II III

DNA Vaccine Technology GX-188E Cervical pre-cancer

therapeutic DNA vaccine HPV DNA vaccine Ichor Medical Systems

hyFcTechnology

GX-H9 Growth hormone deficiency therapeutic Long acting hGH Handok

GX-E2 Anemia Long acting EPO Green CrossGX-G3 Neutropenia Long acting G-CSF ILKOGENGX-P2 Autoimmune Diseases PD-L1(PD-1 agonist) -GX-F7 Hemophilia Long acting Factor XII HandokGX-I7 Infectious Diseases Long acting IL-7 -GX-G6 Type 2 Diabetes Long acting GLP-1 -

Pharmaceutical

Pharmaceutical

2120

CONTACT US

Sung-Ick ParkGeneral managerBusiness Development Division • Phone : +82-31-260-9358 • Fax : +82-31-260-9408• E-Mail : parksi@greencross.com

Hong-kwon Woo, Manager,Global Business TeamOverseas Business• Phone : +82-31-260-9415 • Fax : +82-31-260-9491• E-Mail : overseas@greencross.com

Green Cross is an exemplary R&D-oriented company that leads the biotechnology industry in Korea. This is clear given what Green Cross has achieved since its foundation in 1967.GCC has pioneered in the field of biopharmaceuticals, such as vaccines, plasma-derivatives, diagnostics, recombinant proteins and therapeutic antibodies. GCC has been well known for the R&D and commercialization of ‘HepavaxTM B’, a world’s biggest selling hepatitis B vaccine, ‘HantavaxTM’, a world’s first epidemic hemorrhagic fever vaccine, and ‘SuduvaxTM’, a world’s second chicken pox vaccine. A complete flu pipeline includes seasonal flu vaccine (GCFLUTM), H1N1 vaccine, avian flu vaccine and etc. GCC is also pursuing opportunities in rare diseases developing therapies for Hunter syndrome (HunteraseTM) and Fabry disease (GC1119). With continuous investment in R&D, its portfolio now includes gene/cell therapeutics and small molecule drugs. In 2011, GCC earned $616 million in revenue recording it as 3rd largest Korean pharmaceutical company and invested $51.7 million in R&D which is one of the highest in Korea.

ProductsPlasma Fractions & RecombinantsStarting from the nation’s first Albumin production in 1971, Green Cross currently manufactures more than 12 plasma fractions including immunoglobulin, anti-hemophilic factors, and anti-thrombin factor. Recent innovations include ‘BDD rhFVIII (GreenGeneTM F)’, a 3rd Generation of recombinant Factor VIII for hemophilia A treatment.

VaccinesWe succeeded to develop the world’s third Hepatitis B vaccine in 1983, the world’s first epidemic hemorrhagic fever vaccine in 1988. With the construction of Hwasun plant, a vaccine-oriented manufacturing facility, the influenza vaccine GC FluTM became the fourth in the world to obtain PQ (Pre-Qualification) approval from the WHO.

ETC& OTC MedicinesGreen Cross has provided a broad range of ethical medicines in the field of cardiovascular disease, cerebrovasculardisease, metabolic disease including diabetes, hypertensive disease. Along with poultices (one of our core OTCproducts), we also have provided OTC products in respiratory, dermatology and immunology.

R&D Pipeline

· Company Green Cross Corp.· CEO Il-Sup, Huh· Specialty Plasma Derivatives & Recombinant Proteins, Vaccines, ETC& OTC Products· Location 303 Bojeong-dong, Giheung-gu, Yongin, Korea· Homepage www.greencross.com

Development of Medications That Are Difficult to Produce but Necessary

Green Cross Corp.

Project Indication R NC IND Ph I Ph II Ph III NDA A MGCFLU™ Seasonal fluGC1109 AnthraxGC1107 Tetanus, diphteria

GC3104A D.T.P prophylaxisGC3106A Seasonal flu(Cell culture)

GreenGene™ F Hemophilia A

Hunterase™ Hunter syndrome

IVIG-SN Infections

GCPGC NeutropeniaGC1113 AnemiaGC1119 Fabry DiseaseGC2107 Anti-thromboticsMG4101 Cancer

US

US

USProtein

Cell therapy

Pharmaceutical

Pharmaceutical

2322

CONTACT US

Soonim Lee, Director• Phone : +82-2-2204-1753• E-mail : silee@hanall.co.kr

HanAll BioPharma is a R&D-oriented pharmaceutical company, currently listed on the Korean Stock Exchange (KOSPI).

R&D PipelineProduct Information

HL156CAN

HL156Can, a mitochondrial primer, is a New Chemical Entity (NCE) targeting cancer metabolism, inhibiting mitochondrial OXPHOS system. This inhibition leads to ATP depletion, which increases metabolic stress in cancer cells. HL156Can exhibits cytotoxic effect in cancer cells with defected AMPK signaling function and cytostatic effect in cancer cells with normal AMPK signaling function. HanAll has confirmed potential efficacy of HL156Can to overcome resistance in number of selected cell lines. Currently, HanAll is conducting in-vivo experiments with LKB1 -/- (NSCLC) xenograft model, Braf V600E inhibitor resistant melanoma xenograft model, and lapatinib resistant xenograft model.

*Preclinical Stage (Aug. 2013)

HL036

HL036 is TNF-alpha receptor fragment for the treatment of local inflammatory diseases caused by TNF-alpha such as uveitis, dry eyes, and AMD. Current systemic anti-TNF drugs’ limitations include small volume of distribution and adverse drug events due to high dosage. Therefore, by utilizing fragment, HanAll’s TNF receptor fragment will have greater volume of distribution when administered topically compared to currently marketed anti-TNF-alpha products having larger molecular size. Furthermore, via protein engineering, HL036 will have greater affinity to allow smaller doses and increase the efficacy. It is anticipated that higher concentrations of HL036 will be found in targeted ocular areas when administered topically, preventing systemic ADEs. HanAll aims to utilize this unique property of HL036 for the indication of dry eyes by developing ophthalmic solution.

*Preclinical Stage (Aug. 2013)

HL161

HanAll is currently developing fully human monoclonal antibodies targeting the Fc Neonatal Receptor (FcRn) for the treatment of autoimmune diseases caused by IgG autoantibodies. FcRn plays an essential role in IgG homeostasis by regulating a salvage pathway that prevents lysosomal degradation of IgG, thus contributing to a long half-life in the circulation. While FcRn-mediated half-life extension is beneficial for IgG antibody responses against pathogens, it also prolongs the serum half-life of IgG autoantibodies and thus promotes tissue damage in autoimmune diseases.Hence, HL161 will reduce overall concentration of IgG by blocking FcRn, leading to reduced levels of pathogenic IgG.

*Preclinical Stage (Aug. 2013)

HL009

HL009, adenosylcobalamin liposomal gel, has three different potential mechanisms of actions for the treatment of atopic dermatitis. HL009 can bind to nitric oxide (NO) which causes dermatitis; also it can inhibit inducible nitric oxide synthase (iNOS) to further reduce NO levels. From an immunology perspective, HL009 can activate T regulatory cells which excrete IL-10 and TGF-beta suppressing immune response. Adenosylcobalamin has low permeability through skin due to its large molecular size and relatively high hydrophilicity. Thus, HanAll has formulated adenosylcobalamin topical product utilizing liposomal formulation technology. Benefits of liposomal formulation technology include improved stability, enhanced skin penetration due to increased lipophilicity, and reduced skin irritation by using lipids with proven safety.

*KR Phase II (complete) / US Phase II (complete) (Aug. 2013)

HL040

HL040, a fixed dose combination product, is composed of atorvastatin and losartan for the treatment of hyperlipidemia and hypertension. HanAll finished the phase I study, and currently conducting phase III trial in Korea and phase I study in US.

*KR Phase III (In-progress) / US Phase I (complete) (Aug. 2013)

· Company HanAll BioPharma Co. Ltd.· CEO Dr. Sungwuk Kim

Dr. Seungkook Park· Specialty 1) Oncology & Fibrotic Disease 2) Infectious Diseases 3) Immunology 4) Endocrinology· Location 11-10 Sincheon-dong, Songpa-gu, Seoul, Korea· Homepage www.hanallbiopharma.com

Innovative Medicines to Improve the Quality of Human Life

HanAll BioPharma Co. Ltd.

US BRANCH

S. T. Oh, Director• Phone : +1-301-738-3980• E-mail : stoh@hanall.co.krHPI. Inc.9605 Medical Center Drive, Suite #290Rockville, MD, 20850

Pharmaceutical

Pharmaceutical

2322

HANDOK (Chairman & CEO Young-Jin Kim), a leading innovation-driven pharmaceutical/health-care company in Korea, develops, manufactures and distributes healthcare solutions to improve the health and quality of human life. Handok has a core business focus in diabetes, cardiovascular, muscular skeletal, psychoneurotic disease, human vaccines, medical devices, diagnostics and consumer health. Handok, founded in 1954, grew as a joint venture with Hoechst/Aventis/Sanofi from 1964 to 2012. Handok has also established strategic collaborations in several areas with multiple multinational pharmaceutical companies. For more information, please visit www.handok.co.kr.

Main Products Amaryl M(Glimepiride + Metformin HCl) - The first fixed dose combination of glimepiride and metformin HCl in Korea. - provides glycemic control with favorable safety profile. - registered in 90 countries and exported to 14 countries.

Amaryl Mex(Glimepiride + Metformin HCl) - The first patented sustained-release fixed dose combination of glimepiride and metformin HCl. (Winner of

Korea New Drug Award, 2009) - applied by DRM technology (Dual Release Micro-coating Technology). - registered by 74 countries and exported to 6 countries.

Ketotop Plaster (Ketoprofen) - No. 1 plaster for arthritis and muscular pain in Korea - Patent in 15 countries and Launched in 4 countries

R&D Pipeline

CONTACT US

SoHyun Kwon Head of Licensing & Business Development • E-mail : SoHyun.Kwon@handok.com

· Company HANDOK Inc.· CEO Kim YoungJin · Specialty Pharmaceutical product(ETC, OTC), Medical devices· Location 132, Teheran street, Gangnamgu, SEOUL, 135-923· Homepage www.handok.co.kr

Amaryl M

Amaryl Mex

Project Indication Discovery Pre-clinical Phase I Phase II Phase III

HL5171 Cancer

HL5201 Diabetes/Metabolism

HL3715 Diabetes

HL3501 Glaucoma

HL5945 Alopecia

HL2351 Auto-inflammatory disorders

HL2356 Growth Hormone Deficiency

HL2353 Hemophilia

HL1513 Diabetes

Small moleculesBiologics

The Health Innovator

HANDOK Inc.

Launch in 2015

Collaboration with Genexine

Ketotop Plaster

Pharmaceutical

Pharmaceutical

2524

With the corporate mission of protecting the precious human life from various forms of diseases, HANLIM has consistently endeavored to improve the health standards of people, and we have grown to become one of the leading companies in Korea.In 1993, the future-oriented GMP factory was completed together with the founding of the central research center. As a part of the long-term investment scheme of the company, we continue to make a great investment in accumulating advanced technologies and reorganizing manufacturing facilities lately to enhance the health of mankind as a leading pharmaceutical company.

Products[1] POSOD EYE DROPS : Anti-cataract (Potassium iodide 3mg, sodium iodide 3mg)- Treatment of opacity and hemorrhage of vitreous body caused by aging, myopia, hypertension, diabetes,

periphlebitis and lens opacity as early symptom of senile cataract.

[2] NASAFLEX NASAL SPRAY : Anti-allergic rhinitis agent (Mometasone furoate 0.5mg, Azelastine HCl 1.4 mg)- Perennial allergic rhinitis

[3] RISENEX PLUS TAB : Anti-osteoporosis agent including Vitamin D (Sodium Risedronate 35mg, Cholecalciferol 5,600IU)

- Treatment and prevention of postmenopausal osteoporosis- Treatment of osteoporosis in men

[4] DAGES CAP. : Digestives (Pepsin 25mg, Papain 50mg, Diastase 15mg, Cellulase 15mg, Pancreatin 50mg, Pancrelipase 13mg, UDCA 25mg)

- Insufficiency of gastric, enteric and pancreatic secretion- Anorexia, meteorism, flatulence, steatorrhea, fermentative, dyspepsia with intestinal irregularity - Dyspepsia in cholecystectomized patient- Superalimentation during convalescence and fattening diets- Insufficiency of biliary secretion - Cholelithiasis, cholecystitis, cholangitis, jaundice

R&D PipelineCategory Products Indication Development stage

Incrementally modified

drugs

HL-CER osteoarthritis phase IHL-SAS hypertension phase IHL-PIF hyperlipidemia phase III

Entelon osteoarthritis phase III

New drugsHL-217 AMD phase IHL301 acute/chronic bronchitis phase III

Contact Information

SUNG DAE, KIM (Manager / Overseas trade)• Phone : (822) 3489-6127• E-Mail : sdkim@hanlim.com

POSOD EYE DROPS

DAGES CAP

NASAFLEXNASAL SPRAY

RISENEXPLUS TAB

Thinking of the Human Health and the Future

HANLIM PHARM. CO., LTD.

· Company HANLIM PHARM. CO., LTD.· CEO JAE YOON, KIM· Specialty Business R&D and manufacturing of API/BPIs, pharmaceutical product· Location 42, 52 Gil, Seochodaero, Seocho-Gu, Seoul, Korea· Homepage http://www.hanlim.com

Pharmaceutical

Pharmaceutical

2524

Established in 1973, Hanmi Pharmaceutical now is the No.1 R&D focused pharmaceutical company in Korea with highest R&D investment for many years.Hanmi Pharm. Co., Ltd. is a Korea-based global pharmaceutical company focused on the development and commercialization of new pharmaceutical products. The Company is fully integrated from R&D through manufacturing, marketing and sales with an established presence in Korea as well as China. The Company invests over 16% of its sales in R&D and has over 20 programs in clinical development in three main areas: 1) novel long-acting biologics based on the Company’s LAPSCOVERY™ platform that aim to shift treatment paradigm of diabetes and obesity with weekly insulin, weekly to monthly GLP-1, and their combinations (Quantum Project); 2) novel targeted agents against cancer and autoimmune disorders; and 3) fixed-dose combination programs. The Company has collaboration with global partners on various co-development and business opportunities.

R&D PipelineFocus on Metabolic & Cancer area for New Biologics

Category Candidates Characteristics ResearchClinical

Pre-clinical I II III

Diabetes /Obesity

HM11260C(LAPSCA-Exendin-4)

- Long-acting CA-Exendin-4 analog- Once a week ~ month administration;

T2DM / ObesityHM12470

(LAPSInsulin115)- Long-acting Insulin analog- Once a week administration; T1DM/T2DM

Combination(LAPSInsulin/LAPSExd-4)

- Long-acting Insulin/Exendin-4 Combination- Once a week administration; T2DM

HM12525A(LAPSGLP/GCG)

- Long-acting GLP/GCG- Once a week administration; Obesity / T2DM

Endocrine Disease

HM10560A(LAPSrhGH)

- Long-acting rhGH- Once a week administration; Growth disorder

OncologyHM10460A(LAPSGCSF)

(Licensed-Out)

- Long-acting GCSF analog- Every three weeks administration;

Neutropenia

Focus on oncology & autoimmune area for NCEs

Category Candidates Characteristics ResearchClinical

Pre-clinical I II III

Oncology

Oraxol(Licensed-Out

WW ex. KR, IN)

- Oral Paclitaxel with HM30181A- Reduced side effects, Neurotoxicity

Oratecan(Licensed-Out

WW ex. KR, IN)

- Oral Irinotecan with HM30181A- Increased efficacy & Reduced AE

HM781-36B(Licensed-Out China)

- pan-Her kinase inhibitor- Her-2 & EGFR driven cancers

HM61713 - EGFR mutant selective inhibitor- Reduced side effects

HM95573 - RAF inhibitor- BRAF mut & N-RAS mut driven cancer

KX2-391(Licensed-in)

- Src kinase / tubulin dual inhibitor- Increased efficacy & Reduced AE

AutoImmune HM71224 - BTK inhibitor

- Potent, selective & efficacious for RA

· Company Hanmi Pharmaceutical. Co., Ltd.· CEO Gwan-Sun Lee· Specialty R&D based pharmaceutical products· Location 14, Wiryeseong-daero, Songpa-gu, Seoul, 138-724, Korea· Homepage www.hanmipharm.com

CONTACT US

Licensing outJoshua YangSenior Manager, Global Business Development • Phone : +82-2-410-9087• E-mail : jwyang@hanmi.co.kr

Licensing InBrian JoHead of R&BD• Phone : +82-2-410-9232• E-mail : jo_brian@hanmi.co.kr

Export (Finished Products/APIs/CMO Business)Steven ChoPart Leader• Phone : +82-2-410-0462• E-mail : haamincho@hanmi.co.kr

Information ManagementKyoung Woo Lee R&BD Manager• Phone : +82-2-410-9291 • E-mail : sakshi2@hanmi.co.kr

R&D Driven Pioneer for Innovation in Life Sciences

Hanmi Pharmaceutical. Co., Ltd.

Esomezol Cap.

Amosartan Tab

US, EU

EU

EU

US

US, EU, KR

KR: Gastric |cancer

KR: Colon cancer

KR: NSCLC , Gastric, & Breast cancer

KR: NSCLC

KR: Gastric & Breast cancer

EU: RA

Pharmaceutical

Pharmaceutical

2726

Huons, started as Kwang Myung Pharm in 1965, has grown to a competent global company, producing original and effective essential medicine and medical products, through continual challenges and innovation over 50years.Huons is putting a ceaseless effort for human healthy life without disease.Our goal is to achieve 1billion USD in 2020 and aiming to be the TOP 10 global company at the industry in Korea.To prepare the future, Huons built new factory in 2009. Huons has constructed state-of-the art manufacturing facility in compliance with Korea, US and cGMP. Huons is increasing the investment on innovative research and development. Huons, having obtained many patents as the results of its research, is not becoming complacent and is working hard for development of new medicines, with the global pharmaceutical market entrance. Huons has been producing Local anesthesia as major product and others, supplying it to more than 30countries all over the world.Huons has also been pioneering overseas markets and is making a big progress.

Foundation· In 1965 (Established as a name of Kwang Myung Pharmaceutical)· In 2003 (Changed its name as HUONS which means ‘HUman - MedicatiON - Solution”)

Specialty Business· Manufacturing Pharmaceuticals (including Injections, Dental Anesthetics, Plastic Ampoules, Eye Drops)· Well-being Products· Medical Devices · CMO· Domestic and Overseas Sales & Marketing

R&D PipelineCategory Composition Indication Remark

New DrugHL-09 Magnoliae Cortex Ext. Fatty Liver P2

HSP23 Lonicera Japonica T. Ext. Sepsis P1 HU-017(NCE) IBD Pre-Clinical

IMDs

Cyclosporine combination drug Dry eye syndrome Pre-Clinical New combination drug Melasma Pre-Clinical

NSAID combination drug Acute low back pain Pre-Clinical Amlodipine besylate 6.944mg +

Losartan K 100mg Hypertension P1

Sildenafil combination drug Erectile dysfunction, premature ejaculation P1 Vitis vinifera Extract 50mg Hemorrhoidal, Phlebitis & Varicose Prep. P3

Sodium hyaluronate 60mg/3mL Osteoarthritis (Single injection treatment) Pre-Clinical Biologics Botulinum toxin type A Temporary improvement of glabellar lines Pre-Clinical

Global business · Exclusive Distribution Agreement with Alcon, US (Korean Branch) for Kynex and HE-10 · Exclusive Distribution Agreement with Spectra, USA for Lidocaine & Sodium Chloride· Exclusive Distribution Agreement with Nipro, Japan for Lidocaine Ctg. · Co-promotion with Kabi, Germany (Korean Branch) for Fresofol MCT Injection · Exclusive Distribution Agreement with Biosyn, Germany for Selenase

KYNEX Eye-drop

MEDICAINE Injection

HEALTHCARE INNOVATOR

HUONS CO., LTD.

ALLOON Tablet

CONTACT US

Taek Keun, Yoo (General Manager / Export team)• Phone: +82-2-854-4700• Fax: +82-2-6455-0740• E-mail : intbiz@huons.com

· Company HUONS CO., LTD.· CEO Jae Kap, Jun· Head Office 901 Pangyo innovalley C, 253, Pangyo-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, Republic of Korea· Homepage www.huons.com

Pharmaceutical

Pharmaceutical

2726

CONTACT US

Edward Kim Business Development Team Manager• Phone : +82-2-2600-3848 • E-Mail : edward.kim@biopharmartis.com

With the long history since 1965, Hyundai Pharmaceutical Group (here after HDP) has been growing up for the best R&D pharmaceutical company in Korea and now heading to the world beyond Asia.HDP is committed to creating the best value for mankind through its innovative product development, humanistic management and social responsibilities. Through relentless pursuit of innovative effort, we have been given for several renown awards such as Best Enterprise by Korean Management Association in 1984, the Best Productivity Company among all listed companies in Korea in 1997, the President Award in National Safe and Quality Management in 2005 and 2009 and lately selected as the Advanced technology center (ATC) and innovative pharmaceutical company in 2012 by Korean government. With these recognitions, as well as our strengths in manufacturing, qualified human resources and capabilities to develop innovative pharmaceutical products, HDP has demonstrated and is now fully ready to go beyond Asian border ourselves and with our esteemed global partners.

ProductsTherapeutic Class Product name Composition Indication Company

Cardiovasculardisease

SYSCOR ER nisoldipine Hypertension Bayer

ZESTRIL TAB anhydrous lisinopril Coronary Heart DiseaseAstrazeneca

TENORMIN/TENORETIC atenolol/atenolol&chlorthalidone Hypertension

TAREG/CO-TAREG valsartan/valsartan and HCTZ Hypertension Novartis

Respiratory

LEVOTUSS SYR/TAB levodropropizine Acute and Chronic Bronchitis Dompe

SURFOLASE CAP acebrophylline Acute and Chronic Bronchitis Poli

ALEGYSAL DRY TAB pemirolast potassium Allergy MTPC

Central nervoussystem

ACTIC ORAL TAB fentanyl citrate Breakthrough cancer pain Teva

TAMIRINE TAB galantamine hydrobromide Anti-Dementia

HDPPAXETIL TAB/CR TAB paroxetine HCl Antidepressant

MIRAP TAB pramipexole dihydrocholoride Anti-Parkinson

Women’s health

NORLEVO 1 TAB levonorgestrel Emergency Contraceptive

HRAELLAONE TAB ulipristal acetate Emergency Contraceptive

GYNOFLOR VAG TAB estriol, lactobacillus Vaginal Infection

HemostaticsTACHOCOMB aprotinin, collagen, fibrinogen, thrombin Hemorrhage during surgery

TakedaTACHOSIL collagen, fibrinogen, thrombin Hemorrhage during surgery

Ophthalmologicals OCUVITE ascorbic acid, beta-carotene, etc. Supplement (OTC) Bausch &Lomb

· Company Hyundai Pharmaceutical Co., Ltd.· CEO Chang Hyun, Yoon· Specialty Research and Development of new medicine and incrementally modified drug(IMD)· Location Hyundai Pharm Bldg, Bongeunsa Street 135, Gangnam-Gu, Seoul, Korea · Homepage http://www.hyundaipharm.co.kr

R&D PipelineCriteria Products Indication Type DS PC Ph I Ph II Ph III NDA

NCEHOB-046 Type2 Diabetes 11 betaHSDIHOB-047 Type2 Diabetes GPCRHD-003 Chronic Renal Insufficiency Anti-oxidant

IMD

HOB-060 Obesity Natural compoundHOB-048 Cough Suppressant Peripheral antitussiveHOB-051 Bronchitis Mucos-activeHT-003 CNS Natural compoundBPS-015 Epilepsy Voltage-gated sodium channelsBPS-006 Gastroduodenal Ulcer Antiulcerant Mucosal Protection

The Company Which Has Dream of Healthy Society

Hyundai Pharmaceutical Co., Ltd.

Pharmaceutical

Pharmaceutical

2928

CONTACT US

Sun Park. Ph. D.General Manager / Licensing Team• Phone : +82-2-570-3787• Fax : +82-2-570-3890 • E-Mail : spark@ilyang.co.kr

IL-Yang will exert its efforts towards improving the national health and welfare through continuous research and efforts for the development of the most advanced medicines until all diseases in this land will be treated.IL-Yang Pharmaceutical Co., LTD has tried its almost to manufacture superior medicines for the last half a century. Since it took the first step to supply medicines in Korea, a barren land for the medical industry in 1946, IL-Yang has been advancing into a top-ranking pharmaceutical company in the world with developing on GI, Hematology, Vaccine, Virology area as well as vaccine plant established in April 2011 which has production capacity of 60mil doses per year. On the basis of the most advanced medical practice and pharmaceutical dispensing and a solid business footing in Korean market. IL-Yang has exported a variety of pharmaceuticals to approximately 30 countries in the world including USA and Europe, and has opened an era of overseas branch production by establishing YANGZHOU IL-YANG PHARM. CO., LTD. And TONGHUA IL-YANG HEALTH PRODUCTS CO., LTD. for manufacturing end-pharmaceuticals in China.

Products1. Supect (API: Radotinib)1) 18th New Drug developed in Korea (4th in the world, 1st in Asia)2) 2nd generation BCR-ABL1 tyrosine kinase inhibitor(TKI) for the treatment of Philadelphia chromosome

positive(Ph(+))CML3) Indication: Ph(+) chronic myeloid leukemia (CML) in chronic phase (CP) 4) Development stage: - 2nd line therapy for CML-CP NDA approved in Korea by MFDS in 5th JAN, 2012. - Phase III for newly-diagnosed CML-CP is ongoing in Korea, Thailand, Indonesia, and Philippines5) Key features - Low frequency serious adverse events - Early and high response - High overall survival rate2. Noltec (API: Ilaprazole)1) 14th New Drug developed in Korea2) Noltec is a Proton Pump Inhibitor (PPI) that controls the secretion of gastric acid for the treatment of GU, DU,

GERD/EE, H. Pyrori and NERD3) Expert Opinion: “Ilaprazole, developed to overcome the limitations of currently available PPI’s”4) Key features - Greater effect on Severe GERD/EE patients - Low reoccurrence - Cure symptoms of night time heartburn - Low DDI3. Anti-Viral agentIY7640 has been announced at American Society for Virology on 22 July, 2012 that it is 20~30 times potent than Tamiflu

Supect

Noltec

· Company IL-YANG PHARMACEUTICAL CO., LTD.· CEO DONG YEON, KIM· Specialty Urology, GI, Dermatology, Oncology, Vaccine, Biopharmaceutical· Location IL-Yang Bldg. 544-5 Dogok-dong, Gangnam-gu, Seoul, Korea· Homepage www.ilyang.co.kr

Respect Humanity, Promote Human’s Health,Improve Welfare

IL-YANG PHARMACEUTICAL CO., LTD.

R&D PipelineCompound Application Country Pre Ph I Ph II Ph III NDA Marketed

Ilaprazole

GU / DU Korea, China

GERD / EE KoreaUSA

NERD KoreaH.p eradication Korea

Radotinib2nd line CML-CP Korea1st line CML-CP Korea1st line CML-CP China

Virology

Antiviral agent IY7640 KoreaRespiratory Syncytial Virus Korea

Seasonal Flu vaccine KoreaFlu Quadrivalent Vaccine KoreaAvian Flu Vaccine (H7N9) Korea

OngoingOngoing

OngoingOngoing

Ongoing

Ongoing

Pharmaceutical

Pharmaceutical

2928

CONTACT US

Juneyoung Park, Ph.D., VPBusiness Planning & Development• Phone : +82-31-696-4620• Fax : +82-31-696-4690• E-Mail : jpark@isu.co.kr

ISU Abxis is the leading Korean biopharmaceutical company which succeeds in development on the first therapeutic antibody in Korea. ISU Abxis provides the world-class products to MENA and Latin America region and continues to expand its business portfolio by collaboration with the US and EU based pharmaceutical companies. Since 2001, ISU Abxis has established its own platform technologies and product pipelines with a desire of being an axis of all therapeutic antibody industry as its name stands (ABXIS=AntiBody + aXIS). Beginning with the successful development and market-launch of ISU’s first therapeutic antibody in 2006, ISU Abxis has led Korean biopharmaceutical industry specialized in biosimilars and biobetters. Consequently in 2013 and 2014, ISU Abxis launched two biotherapeutics for orphan diseases of Gaucher and Fabry. ISU Abxis has accumulated the world class manufacturing and QC/QA management through the full development and manufacturing experiences in the globally harmonized compliance.ISU’s three products, supplied to around 30 countries including Turkey, India, Algeria and Venezuela, are available as the only alternative against the originator in the world. Furthermore, ISU Abxis operates the mammalian production dedicated cGMP facility as obtained the GMP certificates from Turkey, Brazil, Colombia and a number of major countries in Latin America and Middle East.ISU’s excellent bio-technology expertise provides a global and local potential partner with (1) the higher productivity at CMO level (2-5g/L), (2) development management system enabling the first-in-human IND from the cell line development within 24 months, and (3) higher biosimilarity to its original product. Now ISU Abxis also makes its great efforts in the development of novel biologics for the patients with cancer and hemophilia. Besides the internal development activities, ISU Abxis recently does its best in importing and providing orphan drugs for Korean patients who suffer the lack of treatment option.ISU Abxis will grow its advanced technology based business for difficult-to-treat and orphan disease market both domestically and worldwide.

Product Clotinab® (Abciximab) · Indication: Adjunct to Percutaneous Coronary Intervention (PCI)· The first therapeutic antibody developed in Korea and the world’s second Abciximab· Launched in Korea in 2007 and exported to twelve countries including India, Turkey, Columbia, Venezuela and etc.Abcertin® (Imiglucerase) · Indication: Enzyme Replacement Therapy (ERT) for Gaucher disease (GD) · The first drug for GD developed in Korea and the world’s second Imiglucerase· Launcher in Korea in 2013 and under the registration in around 20 countries Fabagal® (Agalsidase beta) · Indication: Enzyme Replacement Therapy (ERT) for Fabry disease (FD)· The first drug for FD developed in Korea and the world’s second Agalsidase beta· Launched in Korea in 2014Pheburane® (Sodium phenylbutyrate)· Indication: adjunctive therapy in the chronic management of urea cycle disorders· Imported product from EU (under the Korean registration)

· Company ISU Abxis Co., Ltd. · CEO Daeseong Kim · Specialty Biological pharmaceutics development based on the technology platform for biologics and animal cell culture · Location Global R&D Center, Bldg. C 5th Fl. , 22, Daewangpangyo-ro 712beon-gil, Bundang-gu, Seongnam-si, Gyeonggi-do,

463-400, KOREA· Homepage www.abxis.com

Accumulation of High-value Core Technologies in Biotechnology to Develop Future Products

ISU ABXIS

Abcertin®

R&D Pipeline (as of Mar. 2015)Product 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017

Orphan Drug

Clotinab(Anti-thrombotic Treatment)

Abcertin(Gaucher's Disease Treatment)

Biosimilar

Fabagal(Fabry's Disease Treatment)

ISU103(Breast Cancer Treatment)

ISU305(Paroxysmal nocturnal hemoglobinuria)

Novel Drug

ISU104(Hard-to-treat cancer Treatment)

ISU304(Hemophilia Treatment)

R&D Non Clinical Clinical Launching Sales Tech Transfer

Fabagal®

Clotinab®

Minjeong Seong, Assistant Manager Business Development• Phone : +82-31-696-4631• Fax : +82-31-696-4690• E-Mail : mjs@isu.co.kr

Pharmaceutical

Pharmaceutical

3130

Contact Information

Business Development (Licensing) Kyunghee Kim Product Development Planning Product & Business Development Division • Tel: +82-2-840-6703 • E-mail: khkim@jw-pharma.co.kr

Export (APIs/Finished Products/CMO Business) John Lee Chief of Global Sales I Global Business Division • Tel: +82-2-840-6647 • E-mail: johnlee@jw-holdings.co.kr

Research PlanningSung Hwa SonCorporate Planning Office• Phone: +82-2-840-6935• E-mail: sunghwason@jw-holdings.co.kr

JW Group provides pharmaceuticals vital for maintaining the lives of patients such as anticancer drugs and antibiotics, and has developed into a leading pharmaceutical company and global manufacturer of I.V. Solutions. For almost 70 years ever since its foundation in 1945, we focus on healthcare, ETC, OTC, diagnostics, medical equipment. Based on new technologies and services for healthy lives of human beings, JW Pharmaceutical has built up strong sales network across the country and superior pipelines in I.V. solutions, antibiotics, oncology, cardiology, endocrinology, rheumatology, and gout.

Major Export ProductsType Product Group

Finished Product

1. Carbapenem Antibiotics2. Amino Acid Solutions3. General I.V. Solutions & Other Sterile Solutions4. Anticancer Agents5. Antimicrobial & Antifungal Agents6. Gastrointestinal Agents7. Topical8. Multivitamins9. Agents for Antibiotics10. Miscellaneous

API(Active Pharmaceutical Ingredient)

1. Carbapenem Antibiotics: Imipenem/Cilastatin, Meropenem2. Anti-fungals: Ketoconazole, Itraconazole, Fluconazole3. Chiral Products for Custom Synthesis & Specialty Amino Acid4. Miscellaneous

R&D Pipeline

Jump to the World

JW Pharmaceutical Corp.

※ Pipeline represents progress of R&D programs since 2010※ CreaVax RCC® was approved as pharmaceuticals for export

JW is focusing on developing Biologics as well as Small molecules in the areas of oncology, endocrinology and immunology by employing its novel platforms

Category Product Indication DS PC Clinical Trials NDA MKTPI PII PIII

NCE

CWP291Acute myeloma lymphoma

Multiple myelomaURC102 Gout

Guardlet® T2DMTHRUPAS® ODT BPH

ZEPEED® Erectile dysfunction

Biologics

CreaVax RCC® Renal cell carcinomaCreaVax HCC® Hepatocellular carcinomaCreaVax BC® Hepatocellular carcinomaCreaVax RA® Hepatocellular carcinoma

Actemra® Rheumatoid arthritisActemra® SC Rheumatoid arthritis

Fixed-dose combination

Livalo®-V Pitavastatin/ValsartanGuard-Met Anagliptin/Metformin

OthersURGO Dressing Wound healingURGO Filmogel Wound healing

WINUF Injection Total Parental Nutrition

· Company JW Pharmaceutical Corporation· President Kyung Ha Lee· Specialty I.V- solutions, antibiotics, cardiology, endocrinology, gastroenterology, nephrology, urology, and oncology· Location 2477 Nambusunhwan-ro, Seocho-gu, Seoul, Korea· Homepage www.jw-pharma.co.kr

Pharmaceutical

Pharmaceutical

3130

Leading Korean Pharmaceuticals CMO company including Cosmetics and Functional Health Foods. Since founded in 1990 as a joint venture company with Nihon(Japan) Kolmar, Kolmar has grown to the biggest Korean Pharmaceutical contract manufacturer. Kolmar Korea has provided customized contract manufacturing service with customers who want to outsource their pharmaceutical products, cosmetics and healthcare foods to be more competitive and to develop new formulations feasible in the market.

Kolmar’s CMO Service on Pharmaceutical BusinessAll integrated services from the pharmaceutical development to analytical service and clinical Trial service do distribution channel could be collaborated with Kolmar as it provides fast formulation development, scale up manufacturing, strict quality control and just-in-time delivery.

R&DKolmar Korea reinvests more than 6% of net sales into its research and development, grafting 100 years’ worth of R&D know-how into research and development, and leading the latest trend by developing world-class pharmaceuticals, health functional foods and cosmetics. Kolmar Korea has been approved not only in domestic market but in international market for its great and predominant technology.

Global KolmarKolmar Korea has its roots in the world-wide Kolmar Group. The Kolmar Group based on Kolmar Americas Inc., which is the parent organization of Kolmar Group and was established in Milwaukee, Wisconsin, in 1921, has the world-wide network including Kolmar Japan, Korea, and China, showing off the vast scale in the world. In the global network of Kolmar equipped with 100-year-old R&D know-how, the continuous information exchanges are carried out through the regular symposium and academic activities by affiliated research group members, so that latest data concerning marketing may be shared as well as technologies. Also Kolmar Korea takes the initiative in the development history of world-wide pharmaceutical and cosmetic history.

ProductsKolmar Korea has a cutting-edge technology called ‘LIDCAPS’ that enables liquids to fill into hard-shell capsules. The representative products taking advantage of the technology are Lidsen cap.(naproxen), cough-zero cap., Denti-lid cap.(Titrated extract of the unsaponifiable fraction of Zea mays L.), which have been approved by KFDA first in Korea. Besides, Kolmar Korea’s product line-up covers virtually all the therapeutic areas such as cardiovascular system (Amlodapine tab.), dermatologicals (Mitra cap.), genito-urinary system (Taminal cap.), respiratory system (Pellium syrup.), alimentary treat (Panto-K tab.) and metabolism (Glimepirid tab.), etc.

R&D PipelineCategory Candidate Indication Development stage

New Herbal Drug

KKM0801 GI Ulcer Phase IKKM1011 Hypertension Phase IIKKM1012 Diabetes Phase IIKKM1102 Infections Preclinical

Small MoleculesKKM0805 Osteoporosis Phase IKKM0902 Osteoporosis Phase I

Combination ProductKKM1201 Hyperlipidemia Phase IIKKM1202 Benign Prostatic Hyperplasia Phase III

Contact Information

Moon-Su PyoDirector / Global Business Dept.• Phone : +82-2-3485-0497• Fax : +82-2-515-1532• E-mail : mspyo@kolmar.co.kr

Ms. Elena RyuRegional Manager / Global Business Dept.• Phone : +82-2-3485-0397• Fax : +82-2-515-1532• E-mail : elena@kolmar.co.kr

· Company Kolmar Korea Co., Ltd.· CEO Hong-Koo CHO· Specialty Pharmaceuticals/Cosmetics/Health Functional Foods· Location CNI BD 1596-3 Seocho-Dong Seocho-Gu Seoul Korea· Homepage http://www.kolmar.co.kr

Creating the Value of Health and Beauty

Kolmar Korea Co., Ltd.

Pharmaceutical

Pharmaceutical

3332

Korea Otsuka Pharmaceutical is a branch of Otsuka Group International, which was established in Korea in 1982. Korea Otsuka has set as its mission to contribute to Korea’s healthcare industry, in line with which its main products include “Abilify”, an antipsychotic medication, “Mucosta”, a medicine for gastritis and gastric ulcer and “Pletaal”, an antiplatelet agent. Korea otsuka Pharmaceutical (KOP) was started with the construction of the Hyangnam Plant back in 1989. The Plant acquired KGMP(Korea good Manufacturing Practice) and BGMP(Bulk Good Manufacturing Practice) recognition in 1990 and 1999. In 2014,we gained recognition in Europe for our outstanding production capacity with EU-GMP and expanded the scope of exports to Europe in addition to Asia and the Middle east, for the foremost base of Otsuka Pharmaceutical. As of 2014, KOP started promotion of UBIT and POCone, also is currently planning to launch a Perstymab, Deltyba in this year.On 2014, Otsuka Pharmaceutical signed a five-year extension of a Memorandum of Understanding(MOU) wit of South Korea’s Ministry of Health and Welfare for cooperation a Memorandum, With the initial agreement signed on September 9,2009 in order to the domestic development of new products and the advancement of local R&D infrastructure.Korea Otsuka Pharmaceutical has a world-class level of technological power, built upon the systematization of manufacturing facilities and the advancements made in its business processes and synthesis technologies. It currently exports the materials/finished medicines produced with its competitive, technical strengths to Japan and Europe and 10 countries within Southeast Asia. With other multinational pharmaceutical companies tending to look to close down their factories, Korea Otsuka Pharmaceutical is bucking this trends, with plans to expand its exports and diversify its exporting regions by establishing a firmer foothold, with a production base that covers Asia and Middle East, including its synthesis plant for Rebamipide, which was completed in October 2003.

BusinessKorea Otsuka Pharmaceutical has production facilities based in Korea, contributing to its exports to 10 countries, including Japan, China, Philippine and Indonesia. In fact, the company has produced a medicine for global clinical trials, which requires a high-level of technology, and successfully exported this to Japan in 2011.

Korea Otsuka Pharmaceutical’s differentiated clinical development, exports and its role: 1) Korea Otsuka Pharmaceutical has amplified the advantages of clinical development environment of Korea-

China-Japan, improved the efficiency of new medication development and contributed to better healthcare service for Asian by developing a cure for endemic disease in relevant country

2) A development center for anti tuberculosis drug and diagnosis/medicine-taking model

3) Korea Otsuka Pharmaceutical has developed medications best suited for the country (obtained approval for pharmaceutically modified drug, Platelet SR drug and for the world’s first approval for Abilify tablet being efficacious for Indication of child’s diseases through clinical trials with in the country)

4) As a Korean company exporting its products to overseas, Korea Otsuka Pharmaceutical has made a great (26.4 billion won in 2012 and 23.2billion won in 2013, 28.5 billion won in 2014)

CONTACT US

R&D/Export/ProductHan TaegyuClinical Development Team• Phone : +82-2-3287-9203

OthersKim TaejinPlanning Team • Phone : +82-3287-9124

· Company Korea Otsuka Pharmaceutical Co.,Ltd.· CEO Moon, Sung-ho· Specialty The manufacture, sale, import and export of pharmaceuticals and pharmaceutical products· Location 770-9 Yeoksam-dong, Gangnam-gu, Seoul, Korea· Homepage www.otsuka.co.kr

Mucosta Tab.

Abilify Tab.

Pletaal Tab.

Otsuka-people Creating New Products for Better Health Worldwide

Korea Otsuka Pharmaceutical Co.,Ltd.

Pharmaceutical

Pharmaceutical

3332

· Company Korea Otsuka Pharmaceutical Co.,Ltd.· CEO Moon, Sung-ho· Specialty The manufacture, sale, import and export of pharmaceuticals and pharmaceutical products· Location 770-9 Yeoksam-dong, Gangnam-gu, Seoul, Korea· Homepage www.otsuka.co.kr

Company Profile· Establishment Date : Dec. 3, 1987 · Market Sales : $136M (2014)· Number of employees:738 (Jan. 01, 2015) · Growth Rate from 2013 to 2014 :10.3%· Investment in R&D : 12.6% of net sales (2013) · Number of registered products : about 224 items· Incrementally Modified Drug : Clanza®CR, Clavixin®Duo Cap, Cilostan®CR, Kalomin®Tab.

KUP is export-oriented company. KUP is aiming to be not only a local leader but also global leading company by offering wide range of generics as well as differentiated products, incrementally modified drugs.KUP has broad and well balanced portfolio of 244 products and exports 416 different items to 32 countries through global marketing, and oversea manufacturing facilities in USA, Vietnam, and has a business alliance with oversea companies. Especially KUP established manufacturing facility in Alabama, US for manufacturing and distrubuting drugs and health functional foods in 2003. This facility have allowed KUP to expand markets in US, Japan, and Europe with know-hows of FDA regulatory processes.KUP invested in Research&Development. KUP invested about 12% of net sales and 10% of total employees in R&D continuously. KUP is successful developing innovative drugs and commercializing it. As a result, KUP has launched four IMDs - Clanza®CR Tab., Calvixin®Duo Cap., Cilostan®CR Tab., Kalomin®Tab. In addition, KUP has well balanced R&D portfolio including differentiated products of anti-neoplastic, Anti-hypertensive, and Antithrombotic Dugs.KUP has been acknowledged at home and abroad. KUP was nominated as Forbes’ ‘Asia’s 200 Best Under A Billion’ over two consecutive years. KUP is one and only pharmaceutical company in Korea nominated by the Forbes magazine as one of the ‘Asia’s 200 Best Under A Billion’ over two consecutive years (2009~2010). KUP was awarded the Best Drug Research Award in Korea for CilostanCR in 2015.

Main Products (IMD Products)Product (Ingredient/Formulation) Remark

1. Clanza®CR Tab.(Aceclofenac 200mg/

Controlled Release Formulation)

· Indication : Pain caused by rheumatism (Antiinflammatory Analgesic drug)

· Improved dosing regimen from b.i.d. to q.d.· Less side effects of gastrointestinal

2. Cilostan®CR Tab.(Cilostazol 200mg /

Controlled Release Formulation)

· Indication : Ischemic symptoms, Thrombosis (Antithrombotic durgs)

· Improved dosing regimen from b.i.d to q.d.· Reduced side effects of headache & tachycardia

3. Clavixin®Duo Cap.(Clopidogrel 75mg and Aspirin 100mg /

Fixed Dose Combination)

· Indication : Acute coronary syndrome (Antithrombotic durgs)

· Improved patient compliance4. Kalomin® Tab.

(Pelargonium Sidoides(as dry extract) 20mg / New Dosage Formulation)

· Indication : Upper respiratory tract infections (Antitussive)

· Improved patient compliance for adults

R&D PipelineCompound Name Code Use Stage of Developmen

Unigril®CR Tab. UI03SPG300CT Antithrombotic durgs Clinical TrialLevonazine®CR Tab. UI04LDP090CT Antitussive Clinical TrialLosasc® Tab. 5/50, Losasc® Tab. 5/100

UI15AML055MTUI18AML0510MT Anti-hypertensive Clinical Trial

DTX031 UI19DTX031IV Anti-neoplastic Clinical TrialGastin®CR Tab. UI05MSP015CT GI modulator Clinical Trial

Contact Information

Sayong Hong, Department Manager, Department of Business Development & Licensing• Phone : +82-2-558-8612• E-mail : BD@kup.co.kr

· Company Korea United Pharm. Inc.· CEO Duk-Young Kang· Specialty Business Manufacture, Marketing & Sales of Pharmaceuticals and Other Healthcare Products· Location 25-23, Nojanggongdan-Gil, Jeondong-Myeon, Sejong, Korea· Homepage http://www.kup.co.kr

KUP is a Glabal Pharmaceutical Company All around the World

Korea United Pharm. Inc.

Clanza®CR Tab.

Clavixin®Duo Cap.

Cilostan®CR Tab.

Kalomin®Tab.

Pharmaceutical

Pharmaceutical

3534

CONTACT US

YongNam JangR&D Center / Team Manager• E-mail : ynjang@kuhnil.com

Kuhnil Pharm continues to strive to become an unique research-focused global company through development of innovative global biopharmaceuticals, DDS pharmaceuticals, and combination drug products in an effort to improve quality of life in patients.In 2014, Kuhnil received sales approval of 'Circadin' which is the world's only insomnia treatment with the ingredient of melatonin to the Ministry of Food and Drug Safety. Kuhnil has also adopted an unique strategy of advancing into a new and niche areas of pharmaceutical development such as development of a world's first approval of Omacor's new indica-tion called IgA nephropathy as well as developing new indication in the treatment of ulcerative inflammation of the small intestine, for a novel GI drug. In 2005, Kuhnil participated in the clinical program for innovative biopharmaceutical, TheraCIM, in the treatment of NSCLC, subsequently collaborating with Daiichi-Sankyo to initiate the phase 3 trial for gastric cancer in Korea and Japan in the 2nd half of 2012. In addition, Kuhnil has partnered with foreign CROs for the development of interferon-ß biosimilar. A subsidiary Company, Penmix, specializes in penicillin formulation manufacturing. With the opening of Kuhnil's new cGMP injectable formulation manufacturing facility, Kuhnil envisions to become a global CMO company reaching market abroad including Japan and EU, particularly, utilizing Kuhnil's know-how in the areas of lyophillization process.

ProductsKuhnil Pharm possesses pharmaceutical products in a wide selection of therapeutic areas including antibiotics, circula-tory, gastrointestinal, anti-inflammatory, CNS, respiratory, and endocrinology. Penmix, a subsidiary company of Kuhnil Pharm, was recognized for excellence in quality through exportation to all over the world including Japan, Malaysia, Singapore, Vietnam, and etc.

Product Content Major Export Country

Antibiotics

Amocla/Amocla Duo Tab/Syr/inj Amoxicillin Pot.clavulanate

Malaysia/Singapore/Vietnam* Export, 2012Y: 0.5m$

Tabaxin inj. Piperacillin sodium Tazobactam

Philippine, Vietnam* Export, 2012Y: 0.06m$

Acibactam Inj. Amoxicillin Sodium Sulbactam Sodium

Vietnam* Export, 2012Y: 0.04m$

Piperacillin Inj. Piperacillin Sodium Japan* Export, 2011Y: 8.3m$

Pentacillin Inj. Ampicillin Sodium Sulbactam Sodium

Japan/Vietnam/Philippine* Export, 2011Y: 14.0m$

Cardio Vascular Omacor Cap Omega-3-acid ethyl estersHypnotics Circadin Tab melatonin

RespiratoryPulmican Respule Budesonide micronizedFormerol Dry Syr.

Formoterol fumarateFormerol Dry Syr.

Formoterol fumarate

Muscle relaxants Thiosina Tablet Thiocolchicoside Amorphous aescin

Lodine kuhnil Cap/Tab/SR Tab Eodolac Micronized

Gastrointestinal Wellcon Tab. Calcium polycarbophilBioflor 250 Pow Saccharomyces boulardii

R&D PipelineProduct Indication Preclinical Phase I Phase II Phase III Launch

OncologyKI 0501 Stomach CancerKI 0508 Pancreatic Cancer

QOLKI 1001 InsomniaKI 239 Female Sexual Desire DisorderKI 208 Night Eating SyndromeKI 251 Premature Ejaculation

Cardio VascularKI 1105 DyslipidemiaKI 1106 DyslipidemiaKI 1107 Dyslipidemia

DentalKI 1209 Periodontitis

· Company Kuhnil Pharmaceutical Co.,Ltd· CEO Kim Young Joong· Specialty

BusinessDevelopment, Manufacturing, and Distribution of Various Pharmaceutical Products including Oral Dosage Forms, Injectables, Inhalers, etc.

· Head Office OhSong B/D, 14, Jeongdong-gil, Jung-gu, Seoul, Korea, 100-120· Homepage www.kuhnil.com

Amocla/Amocla DuoTab/Syr/inj

Tabaxin inj.

Piperacillin Inj.

Pentacillin Inj.

Pulmican Respule

Thiosina Tablet

Global pharmaceutical company committed in providing better quality of life for people.

Kuhnil Pharm., Co.., Ltd.

P3

Launch

P3Preclinical

P1

P3

PreclinicalPreclinicalPreclinical

Preclinical

Preclinical

Pharmaceutical

Pharmaceutical

3534

The First Pioneer in Korean Pharmaceutical R&D Products LG Life Sciences is Korea’s leading biopharmaceutical company. One of LG Group affi liate, demerged from LGChem in 2002. LGLS is leveraging its proven R&D capabilities to develop world-class products, Factive®, the onlyUS FDA approved novel chemical drug, as well as Valtropin®, the fi rst biosimilar approved by the EMEA and USFDA developed in Korea. LGLS is building a network of strategic alliances to extend its R&D and marketing reach.

ProductsFactive® - Fast Active, the most potent quinolone antibiotic in the world, commercialized in over 30 countries worldwideZemiglo® - A novel dipeptidyl peptidase IV (DPP IV) inhibitor for T2DM with good efficacy and safety profiles. Approved by the KFDA in June, 2012Eutropin® - The right choice for managing short stature recombinant human growth hormone with proven efficacy and

safety since 1993Espogen® - Human recombinant erythropoietin, safe and effective treatment for anemia of chronic renal failureFollitrope® - Recombinant FSH, used in the treatment of female infertility in controlled ovarian hyperstimulation to induce

the development of multiple follicles in a medically assisted reproduction program as well as anovulationHyruan Plus® - High molecular weight hyaluronic acid viscosupplement made by microbial fermentation for low side-effect,

quality proven by EMEA and CE marking

R&D PipelineSR-hGH - The world’s fi rst once-a-week human growth hormone, US NDA has been fi led for adult and multinational

phase III trials are fi nished for pediatric GHDMonoclonal Antibody Biosimilars - Enbrel, Humira and Avastin biosimilars are undergoing active development1) Chemicals

Class Product Indication DS PC Clinical Trial NDAPI PII PIII

NCE

LC280126 Myocardial Infarction ○LC350189 Hyperuricemia, Gout ○LC51SPA Multiple Sclerosis ○LC52CIS Type 2 Diabetes ○

LC54AID3 Metabolic Disease ○LC53LEOH Multiple Myeloma ○

IMD*

ZV Combi Hypertension ○VR Combi Hypertension / Hyperlipidemia ○ZemiMet Type 2 Diabetes ○ZemiSU Type 2 Diabetes ○

ZemiStatin Diabetes / Hyperlipidemia ○ZemiARB Diabetes / Hypertension ○

2) Biologics

Class Product Indication DS PC Clinical Trial NDAPI PII PIIIBiobetter LB03002 GHD (global) ○

Biosimilar

LBEC0101 Rheumatoid Arthritis ○LBAL Rheumatoid Arthritis ○LBDP Anemia ○LBBZ Colorectal Cancer ○

Vaccine

DTwP-HepB-Hib (liquid) D/T/P/HBV/M ○LBFL0101 Influenza ○

LBVC Poliomyelitis ○LBVD D/T/P/HBV/M/IPV ○LBVE Pneumonia ○

HA-based ProductLBSA0103 Osteoarthritis ○

YVOIRE contour Plus Soft Tissue Augmentation ○

Jong-heon Won, ManagerBusiness Development Team• Phone : +82-2-6924-3233• E-Mail : jhwon@lgls.com

· Company LG Life Sciences, Ltd.· CEO Il-Jae Jung· Specialty New chemical entity, biosimilar, Diagnositcs· Location LG Gwanghwamun Bldg. 92, Sinmunno-2ga, Jongno-gu, Seoul, Korea· Homepage www.lgls.com

Factive®

Declage®

Eutropin plus®

Zemiglo®

Euvax B®

Leading Global Life Science Company

LG Life Sciences, Ltd.

CONTACT US

*IMD = Incrementally modified drugs

*HA = Hyaluronic acid

Pharmaceutical

Pharmaceutical

3736

CONTACT US

Ochang Headquarters/Microbial Toxin R&D center• Phone : +82-70-8666-7520• Fax : +82-43-217-1557• E-Mail : yanggh@medytox.com

Seoul Office• Phone : +82-2-3471-8319• Fax : +82-2-3471-8374

We are at the forefront of Korean biopharmaceutical industry, thanks to our excellent R&D capabilities based on our top-tier biotechnologists, and to our state-of-the-art operations and production facilities. Moreover, we are going to become a trailblazer in the field of biotechnology due to our passion and courage to embrace global challenges.

Since Botulinum Toxin Type A Neuronox (Neuronox is also being sold worldwide under different brand names such as Siax, Botulift, Cunox and Meditoxin) was launched in 2006, Medytox has shown a dramatic growth. Since 2009, we have ranked No. 1 market share in Korea and reached near 40% of market share. As more diverse indications are added, it appears that our market share would further increase. Our company has successfully developed the fourth botulinum toxin biopharmaceuticals in the world. We are exporting the products to about 50 countries, including Japan, Thailand, India and Brazil. We are also expecting to be a leading global biopharmaceutical company after entering the North America and EU markets in 2016.

Main Products

1. Botulinum Toxin Type A product Medytox’s core business area is manufacturing botulinum toxin type A biopharmaceuticals, Neuronox. It is

widely used not only in the cosmetic field, including facial wrinkle reduction, but also in the therapeutic field, for people with blepharospasm, cerebral palsy, etc.

2. Hyaluronic Acid Dermal Filler Medytox’s hyaluronic acid filler, Neuramis is currently being used in the field of cosmetics to smoothen deep

and fixed wrinkles on skin tissue. Also, it is used as therapeutic agent for surgery and for treatment of arthritis. As a partner product, it could maximize a synergy effect along with Medytox’s core product Neuronox.

R&D Pipeline

Fueled by the success of Nueronox, we plan to perform a basic study for the development of innovative bio pharmaceuticals to heal degenerative arthritis, senile ocular disease, skin disease and cancer. We have strengthened base technology in protein engineering, antibody engineering and cell biology by recruiting talented personnel. As the first achievement, we have completed basic verification studies on degenerative arthritis and senile ocular disease (MT202 and MT401). It appears that they would enter into the pre-clinical phase in 2013. We plan to keep making investments with a long-term vision to be a global biopharmaceutical leader through development of innovative drugs.

· Company Medytox· CEO Jung Hyun Ho· Specialty Botulinum toxin products, Medical aesthetics, Bio-pharmaceuticals· Location 641-4 Gak-ri, Ochang-eup, Cheongwon-gun, Chungbuk 363-883, Korea· Homepage www.medytox.com

Toxin, Filler and Even More

Medytox

Nueronox®

Pharmaceutical

Pharmaceutical

3736

Bum Kyu, ShinGeneral Manager, Overseas Business Department• Phone : +82-2-3140-0673• Fax : +82-2-392-5315• E-Mail : bk72@samjinpharm.co.kr

Since its establishment in 1968, we, Samjin Pharm Co., Ltd. have strove our utmost efforts for producing qualitative pharmaceuticals and investing to research for the development of a new drugs with a philosophy of company that “Respect for human life”.

GMP Factory The manufacture of pharmaceutical products is the most important field of pharmaceutical industry as well as research and development. The production of pharmaceutical products, which demands the utmost precision and professionalism is a standard to evaluate the level of the pharmaceutical company. The manufacturing factory supports Samjin Pharmaceuticals’ advanced technology as well. In order to maintain the precision of manufacturing the pharmaceuticals, which is sensitive to all kinds of qualification, Samjin Pharmaceutical plant has been operated with the scientific and automatized system in all manufacturing processes.

ProductsSamjin Pharmaceutical is a comprehensive pharmaceutical company of developing, manufacturing and marketing finished products and APIs in the worldwide market. The representative products, “GEWORIN Tablet” has been occupied significant market share in analgesic market in Korea, and Samjin Pharmaceutical has continuously developed a marketing strategy for potential increase in sales and profits with high quality generic pharmaceuticals such as anti-platelet agent “PLATLESS Tablet (Clopidogrel 75mg Tablet)” and Clopidogrel Bisulfate (crystal form 1). Samjin Clopidogrel Bisulfate (crystal form 1) has excellent physico-chemical properties for the direct compression such as narrow particle size distribution, good flowability and good bulk density.

R&D Pipeline1. Development of anti-HIV agent : SJ3366 SJ-3366(IQP-0528) is a unique and highly potent new nonnucleoside reverse transcriptase inhibitor of human

immunodeficiency virus type 1(HIV-1) that also inhibits HIV-2. Also its product is a novel candidate for a vaginal topical microbicides, currently being performed with preclinical study against formulation both a gel and an intravaginal ring.

2. Development of anticancer agent : SJ3902 SJ-3902 Series is a novel, highly potent and safe anticancer agent with unique mechanism of action and

chemical structure suggesting the first member of new pharmacology class of tumor cell cycle interrupt on oncology field. The compound exhibits microtubule-interfering (G2/M), apoptosis, and inhibition of angiogenesis.

3. Development of anti-dry eye agent : SA001 SA001(prodrug) is novel anti-dry eye drug candidate with unique mode of action which is very effective to all stage of

dry eye syndrome by increasing tear volume and anti-inflammatory action through stimulating mucin secretion in the eye

4. Development of anti-diabetes agent : SJ8093 SJ8903 is a novel sodium-glucose co-transporter-2(SGLT-2) inhibitor as a potential anti-diabetic agent.

The compound reduces blood glucose level by blocking glucose reabsorption in the kidney and thereby stimulating excretion glucose via the urine.

5. Development of anti-cancer agent : SI001 SI001 is a target specific anti-cancer agent with an excellent Pan-RAF and VEGFR2 dual inhibitory activity.

The mode of actions of SI001 is dual inhibition of mutant RAS-RAF signaling in colorectal cancer cells and angiogenesis in vascular endothelial cells.

· Company Samjin Pharmaceutical Co., Ltd.· CEO Sung Woo, Lee· Specialty Manufacture, Marketing and Distribution of Pharmaceutical Products (Finished Products and APIs)· Location 338-8, Seogyo-Dong, Mapo-Gu, Seoul, Korea· Homepage www.samjinpharm.co.kr

For the Health Life and Fruitful Future

Samjin Pharmaceutical Co., Ltd.

CONTACT US

Pharmaceutical

Pharmaceutical

3938

Innovative Specialty Pharmaceutical Company

Samyang Biopharmaceuticals Corporation.

CONTACT US

Overseas Pharmaceuticals SalesMr. Jae-Wook JooTeam Leader, Overseas Business Team• Phone : +82-2-740-7163• E-mail : jaewook.joo@samyang.com

API SalesMr. Jeong-Hwan YunSenior Manager, Overseas Business Team• Phone : +82-2-740-7914• E-mail : adrian.yun@samyang.com

Business developmentMr. Gun SeomoonSenior Manager, Overseas Business Team• Phone : +82-2-740-7268• E-mail : gun.seomoon@samyang.com

Samyang Biopharmaceuticals Corporation, with its central research center is engaged in the development and marketing of novel drug delivery systems and medical devices.Samyang Biopharmaceuticals Corporation is focusing its efforts on healthcare as its core strategic business of the 21st century. Samyang Biopharmaceuticals Corporation is developing proprietary and unique core technologies for the development of world class novel drug delivery systems.

Main ProductsCategory Products Active

Ingredient Strength / Grade Comment

Injection

Genexol® PM Paclitaxel 30mg, 100mg · Cremophor-free, Ethanol-free formulationNanoxel® M Docetaxel 20mg, 80mg · Tween-80 free formulation (No diluent vial)

Zolenic® Zoledronic acid 4mg / 5mL · Launched in Korea & Georgia

Generic

Paclitaxel 30mg / 5mL, 100mg / 16.7mL150mg / 25mL, 300mg / 50mL

· Launched in EU (Working as CMO)· All dossiers are ready for approval procedure

Docetaxel 20mg/1mL, 80mg/4mL140mg/7mL, 160mg/8mL · Launched in EU & Japan (Working as CMO)

Oxaliplatin 30mg/5mL, 100mg/16.7mL150mg/25mL, 300mg/50mL

· Launched in EU (Registered in DE, BG, RO, UK)· MRP running for other EU members

PatchFentaderm® Fentanyl 12㎍/hr, 25㎍/hr, 50㎍/hr · Reduced API (50%) with same PK as originalDemenCure® Rivastigmine 4.6mg/day, 9.5mg/day · Reduced API (66%) with same PK as original

APIPaclitaxel EP, USP · CEP completedDocetaxel EP, USP · CEP completed

GMP CertificationsYear Product Inspection Authorty

2014 Paclitaxel (API), Docetaxel (API),Synthetic Paclitaxel (API), Pemetrexed (API) Germany (BGV)

2013 Docetaxel (API) Japan (PMDA)2012 Oncology Injections Germany (BGV)

2010Oncology Injections Japan (PMDA)

Paclitaxel (API) Japan (PMDA)Diclofenac Patch Australia (TGA)

R&D PipelineCategory Technology Description Products Development Status

Injection

Polymeric MicelleGenexol® PMNanoxel® MTemsirolimus

MarketedMarketed

Non-clinical

Polymeric Nano-Particle Docetaxel-PNPVoriconazole-PNP

Clinical (Phase I)Clinical (Phase I)

Long Acting Micro-Particle Goserelin Non-clinical

Trans-dermal TDS (Transdermal Drug Delivery System)

Capsaicin Clinical (Phase II)Fentaderm® MarketedDemenCure® Approved

Buprenorphine Under developmentOral BA enhancing Celecoxib Non-clinical

API

Plant Cell Culture Paclitaxel Marketed

Fermentation EpothilonesSirolimus

Pilot productionUnder development

Fermentation / Organic Synthesis Liraglutide Under development

Organic Synthesis

PaclitaxelDocetaxel

PemetrexedBortezomibCabazitaxel

MarketedMarketedMarketed

Pilot productionUnder development

· Company Samyang Biopharmaceuticals Corporation.· CEO Taeung Eom· Specialty Oncology, GMP Manufacturing(APIs, Injections, Patches), DDS Technology· Head Office 31, Jong-ro 33-gil, Jongno-gu, Seoul, 110-725, Korea· Homepage www.samyangbiopharm.com

Pharmaceutical

Pharmaceutical

3938

SANOFI IS A GLOBAL HEALTHCARE LEADER FOCUSED ON PATIENTS’ NEEDSengaged in the research, development, manufacturing and marketing of innovative therapeutic solutions. Sanofi has core strengths in healthcare, with 7 growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY). In Korea, Sanofi has four legal entities in the fields of pharmaceuticals and consumer healthcare (sanofi-aventis Korea), vaccines (Sanofi Pasteur), rare disease (Genzyme Korea), and animal health (Merial Korea). sanofi-aventis Korea has recognized Korea’s emerging excellence in basic research and sought ways to expand collaboration under “Open Innovation” strategy. Accredited as Innovative Pharmaceutical Company in 2014, sanofi-aventis Korea has established and looked forward to seeking out partnerships with promising pharmaceutical companies, bio-techs, clinical research centers as well as academia in Korea to bring innovation where high unmet patient needs exists, while continuously investing in clinical development of new medicines and help Korean partners go global.

ProductsPlavix®

Atherosclerosis symptomsLantus®

DiabetesAprovel®

Essential hypertension, Renal disease in type 2 diabetes with hypertensionEloxatin®

Colorectal cancer, stomach cancer, pancreatic cancerTaxotere®

Breast cancer, stomach cancer, non-small cell lung cancer, head and neck cancer, ovarian cancer, esophageal cancer and prostate cancer

R&D PipelineMyelofibrosis, Articular cartilage defects, Muscular atrophy, Diabetes, Rheumatoid arthritis, Dyslipidemia, Atopic dermatitis and Asthma

History1973 Founded Sanofi1991 Established Sanofi Korea2004 Established sanofi-aventis Group2005 Established clinical R&D unit under direct control of corporate headquarters 2006 Started sanofi-aventis Korea2010 Launched Cenovis, the consumer healthcare brand2012 Started Sanofi Group Integrated Management Committee2013 Received Family-Friendly Company Accreditation by MOGEF2014 Received Innovative Pharmaceutical Company by MOHW

Global Business Development Ms. Soo Youn ChangHead of Strategy & Business Development• Phone: +82-2-2136-9010• E-mail : Sooyoun.chang@sanofi.com

· Company sanofi-aventis Korea· CEO Kyung-Eun (Kay) Bae· Specialty Diabetes, Oncology, Cardiovascular Disease, Internal Medicine, Central Nerve System, Infectious Disease,

and Rheumatoid arthritis· Tel +82-2-2136-9000· Fax +82-2-2136-9099· Location 235, Banpo-daero, Seoch-gu, Seoul · Homepage www.sanofi.co.kr

CONTACT US

R&D CollaborationDr. Sung Joo LeeHead of Research, TSU Asia Pacific R&D• Phone: +82-42-863-9205• E-mail : Sungjoo.lee@sanofi.com

Plavix®

Lantus®

Aprovel®

Eloxatin®

Taxotere®

We Fulfill Your Healthy Dreams

sanofi-aventis Korea

Pharmaceutical

Pharmaceutical

4140

CONTACT US

Contact InformationPaul Choen, Director• Phone : +82-2-2189-3471• E-mail : jung1@shinpoong.co.kr

Shin Poong is the pharmaceutical company with the No. 1 sales of prescription drugs in the Surgery market.Under the management philosophy of ‘for the health of the people’, Shin Poong Pharm.Co.,Ltd specializes in manufacturing remedy drugs with sincere efforts put into producing every single tablet of life-saving drugs ranging from ingredients to finished products based on our state-of-the-art manufacturing facilities and quality assurance system. We are committed to realizing the spirit of Shin Poong 3V(Vision,Venture and Victory) with top- notch competitiveness based on in-house ingredient synthesizing technologies obtained through rigorous R&D efforts and to further developing the company into the one that receives confidence from our customers and that contributes to promoting the wellbeing of human beings.

In 2011, Shin Poong developed PYRAMAX® in cooperation with Medicines for Malaria Venture and approved by Korean FDA. PYRAMAX® is the first artemisinin combination therapy to receive an Article 58 positive scientific opinion from EMA for treatment of both strains of malaria : P.falciparum and P.vivax, in adults and children over 20kg and was listed on WHO prequalified medicines in may 2012.

Main ProductsName Indication Phase Classification

Pyramax Tab. Anti-malaria On Market NMELoxfen Tab NSAIDs On Market Generic

Hyal Forte Inj Osteoarthritis On Market GenericClamoxin Tab. Anti-biotics On Market Generic

Medicurtain Inj. Adhesion Barrier On Market Medical device

R&D Category Products Indication Stage

NME

Pyramax Tab. Anti-malaria Launch(Korea) Registration(EMA)Pyramax Gran. Anti-malaria Phase 3(Asia, Africa)

SP-8203 Anti-stroke Phase 1 (US/Korea)SP-35454 Osteoporosis Phase 1 (Europe)

IMD

SP5M001 Osteoarthritis Phase 1(Korea)SP3R001 Anti-histamine Phase 1(Korea)SP3C001 Hypertension Phase 2&3(Korea)SP3C002 Hyperlipidemia Phase 3(Korea)

Loxfen Inj. NSAIDs Registration(Korea)Derma filler Derma filler Pre-clinic(US/Korea)-Medical device

※ New Molecular Entity, Incrementally Modified Drug

· Company SHIN POONG PHARM.CO.,LTD· CEO JEI MAN RYU · Specialty Business Manufacture and Sales of the pharmaceutical products· Head Office 748-31 YOKSAM-DONG, KANGNAM-GU, SEOUL, 135-925, KOREA· Homepage www.shinpoong.co.kr

pharmaceutical company with the Top-levelsales of prescription drugs in the Surgery market

Shin Poong Pharm.Co.,Ltd

Hyal Forte inj.

Pyramax Tab.

Clamoxin®

Medicurtain®

Pharmaceutical

Pharmaceutical

4140

CONTACT US

Name : Justis TaeJun Cho General Manager

• Phone : +82-2-2008-2543• E-Mail : justis@sk.com

SK Chemicals contributes to ehance human health and the quality of life by developing new synthetic drugs, premium vaccines and innovative manufacturing technologies. SK Chemicals opened a new chapter in the history of the Korean pharmaceutical industry in 1999, when it succeeded in launching SUNPLA, Korea's and the world's first third generation platinum complex cancer drug. In 2007, the company launched the world's fifth PDE5 inhibitor, a novel erectile dysfunction agent in Korea. In 2011, it also succeeded in commercializing the world first orally dissolving film (ODF) formulation containing the PDE5 inhibitor. In particular, the platform technology of manufacturing not only ODF formulation but also transdermal patch formulation had made SK Chemicals as a leader in developing incrementally modified formulation drugs. As a result, dementia patch called SID710 was successfully approved for sale in Europe. SK Chemicals is actively marketing and exporting the product to major markets. In the virtue of ceaseless investment to its R&D activities, SK Chemicals now possesses a wide range of R&D portfolio from premium vaccines and plasma derived products to recombinant protein drug. Particularly, the next generation technology of cell-culture based vaccine, it succeeded in obtaining the Korea's first marketing authorization of cell-culture technology based influenza vaccine. As a part of continuous commitment to vaccine R&D, it also completed building a state-of-the-art vaccine manufacturing plant in Andong city. As a result, the company already entered into a couple of major licensing agreements with multinational organizations.

Main ProductsProduct Information

Sunpla injection (3rd generation platinum complex anti-cancerdrug)

Anti-cancer agent*The 1st Korean new chemical entity

Trast patch (Piroxicam) Patch formulation with anti-inflammatoryJoins (Clematis mandshurica, Trichosanthes Killilowii, Prunella vulgaris ext)

Cartilage protective agent*The 1st Korean new herbal drug

Mvix (Mirodenafil) Treatment of erectile dysfunction (ED)Rivastigmine patch Patch formulation for Alzheimer’s disease exporting worldwide

SKYCellflu Prevention for influenza virus*The 1st Korean cell culture influenza vaccine

R&D PipelineSK Chemicals focuses on developing premium vaccines, new chemical entities, and biopharmaceutical drug in therapeutic areas with high unmet medical needs.

Product Indication Description StatusNCE401 Fibrosis New Chemical Entity Preclinical NCE403 Endometriosis New Chemical Entity Phase INCE406 Diabetes New Chemical Entity PreclinicalNCE407 Multiple sclerosis New Chemical Entity Screening

YKP Irritable bowel syndrome New Chemical Entity Phase IINBP601 Hemophilia Bio-better Multinational, pre-registrationNBP602 Hepatitis B immunoglobulin Plasma product RegistrationNBP604 Haemophilia Bio-better PreclinicalNBP606 Pneumococcal diseases Vaccine Pre-registrationNBP607 Seasonal cell culture flu Vaccine Approved in 2014

NBP608 Herpes zoster Vaccine RegistrationVaricella Vaccine Phase III

NBP - Vaccine Phase INBP - Vaccine Phase I

HMP301 Asthma Botanical Phase IIISID123 Erectile dysfuction/premature ejaculation Chemical, combination drug Phase I

THVD201 Overactive Bladder Chemical, combination drug Phase IIISID125 Erectile dysfunction Orally dissolving film RegistrationSID132 Osteoarthritis Botanical Phase IIISID142 Chronic arterial occlusion Botanical / chemical Phase ISID122 Parkinson’s disease Patch ScreeningSID141 Pain Patch ScreeningSID143 Stroke, systemic embolism BA enhancing tech ScreeningSID144 Prostatic cancer Microsphere inj. Screening

· Company SK Chemicals Co. Ltd.· CEO Mahn-hoon, Park · Specialty Specially chemicals and life science business· Location 310, Pangyo-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, 463-400 Korea· Homepage www.skchemicals.com

Developing Premium Vaccines, New Chemical Entities, Biopharmaceutical Drugs

SK Chemicals Co. Ltd.

Trast Patch

Joins

Mvix

Sunpla injection

SKYCellflu

Pharmaceutical

Pharmaceutical

4342

“ST Pharm provides reliable and timely custom manufacturing services for API following stringent quality system and close communication with the clients.” Founded in 1983, ST Pharm (formerly known as Samchully Pharmaceutical) has been offering excellent custom manufacturing service of APIs and their intermediates to meet clients’ high expectation for their use in pharmaceutical development in compliance with cGMP requirements. Our reliability in service, which is well-proven through decades of business relationship with many big pharmas and biotech clients, is the essence of our strength along with our expertise in process development and scale-up optimization.

Main Products1. Custom Manufacturing 1) New Drug APIs & Intermediates 2) GMP-Oligonucleotides (for RNA therapeutics)

2. Generic APIs & IntermediatesWith highly experienced technical teams and synergistic collaboration with a parent company, Dong-A Pharmaceutical, ST Pharm extends the product pipelines to generic APIs and intermediates with supportive DMFs and high-spec quality control required to timely enter domestic and global market.

Products List (selected)

Category Products Customer Indication/Stage

New Drug APIs

HCV drug Originator (Worldwide) HCV/Phase 3HIV drug Originator (Worldwide) HIV/MarketedHIV drug Originator (Russia) HIV/Marketed

Oligonucleotide Originator (Worldwide) Oncology/Phase 2

Pharmaceutical Intermediates

Chiral epoxide Originator (Worldwide) HIV/MarketedChloro-(L)-sugar Originator (Worldwide) HBV/Marketed

Nucleoside monomers US/EP/JP Various RNA therapeutics/Clinical

Generic APIs

Stavudine ROW/EU HIV/MarketedTerizidone S.Africa/Germany/CIS Tuberculosis/Marketed

Atorvastatin Domestic/JP/ROW Hyperlipidemia/MarketedClopidogrel Domestic/ROW Anticoagulant/MarketedOlmesartan JP/ROW Hypertension/Marketed

R&D Pipeline (selected)Category Project Goal

CMOAntibiotics Commercial in 2013

Gastritis therapeutics for clinical trialDiabetes therapeutics Commercial in 2014

New DrugAnticancer (CRPC) Pre-clinical in 2014

HIV Pre-clinical in 2014

Generic APIs

Anticancer Released in 2013MRI contrast media Released in 2014

HBV Released in 2015COPD Released in 2016

· Company ST Pharm Co., Ltd.· CEO Geun-Jho Lim· Specialty CMO (New Drug APIs & Intermediates), Generic APIs, Oligo APIs and New Drug Development· Location 7F MSA Bldg., 891-43, Daechi-dong, Gangnam-gu, Seoul, Korea· Homepage http://www.stpharm.co.kr

CONTACT US

Seong-Soo OhChief ResearcherR&D Planning TeamR&D center• Phone : +82-31-488-1409• E-mail : info@stpharm.co.kr

World Leader in API Custom Manufacture

ST Pharm Co., Ltd.

Pharmaceutical

Pharmaceutical

4342

CONTACT US

Jun Hee Lee / Head of Department• Phone: +82-2-799-0072• E-mail: jhlee2@taejoon.co.kr

Taejoon Pharm Co., Ltd. is a leading specialty pharmaceutical company in ophthalmology, contrast media, and gastrointestinal agents with a global presence in Europe, Africa, Asia Pacific Region and the United States of America.

Main ProductsOphthalmic Solution•CYPORIN N (API: CYCLOSPORINE, Nano-technology) – Released date: Feb 2015. - Indication: Increase tear production in patients whose tear production is presumed to be suppressed due to

ocular inflammation associated with keratoconjunctivitis sicca. Increased tear production was not seen in patients currently taking topical anti-inflammatory drugs or using punctual plugs.

•MC FREE (API: SODIUM CARBOXYMETHYLCELLULOSE) – Released date: Sep 2011. - Indication: For the temporary relief of burning, irritation and discomfort due to dryness of the eye or exposure

to wind or sun. May be used as a protectant against further irritation.•XALOST PLUS (API: LATANOPROST+TIMOLOL MALEATE) – Released date: Nov 2005. - Indication: For the reduction of IOP in patients with open-angle glaucoma or ocular hypertension, who are

insufficiently responsive to the topical beta blocker.

Contrast Media•MRbester INJ. (API: GADOPENTETATE DIMEGLUMINE) – Released date: Oct 2004. - Indication: MR imaging for the whole body excluding the heart, central nervous system including the brain,

spine and associated tissues in adults and pediatric patients (2 years of age and older).

•IOBRIX INJ. (API: IOHEXOL) – Released date: Jan 2002. - Indication: Myelography, angiography, urography, contrast enhancement of computerized tomography.•RADISENSE INJ. (API: IOPAMIDOL) – Released date: Jan 2002. - Indication: For cerebral angiography and peripheral arteriography, contrast enhanced computed tomographic

imaging of the head and body, venography, and intravenous excretory urography.

GMP Certification ListNo. GMP Facility Year

1 KGMP Sterile ophthalmic solution 1995, 2010, 2011, 2012, 20142 EU GMP Sterile ophthalmic solution 2008, 2011, 20143 Anvisa GMP Sterile ophthalmic solution 20104 Actavis Audit Vendor audit for sterile ophthalmic solution 20105 NAFDAC GMP Sterile ophthalmic solution 2011

R&D PipelineProduct Name Indications Current Status

Age-related Macular Degeneration (New Biological Entity) AMD Phase 2/3Antibiotic product (New Chemical Entity) Bacterial conjunctivitis Pre-clinicalDry eye product (New Chemical Entity) Dry eye Pre-clinical

Combination or Improved drugs Ophthalmic/GI indications Phase 3 ~ Pre-clinical

· Company TAEJOON PHARM. CO., LTD.· Co-CEO Tae Young Lee / Joon Youb Lee· Specialty Ophthalmic solution, Contrast media, Gastrointestinal agents· Location 8 Daesagwan-ro 31-gil, Yongsan-gu, Seoul, Korea· Homepage www.taejoon.co.kr

Leading Biotech Company for Better Life

TAEJOON PHARM. CO., LTD.

Cyporin N

Xalost Plus

Pharmaceutical

Pharmaceutical

4544

Leading Biotechnology Company Targeting Cardiovascular Disease, Neuropathy, Cancer and Immune-related Disorder.

ViroMed Co., Ltd.

Contact Information

Youngtae Hong Section Chief, Strategic Business Development • E-mail : yotih@viromed.co.kr

ViroMed Co., Ltd. (ViroMed), a leading biopharmaceutical company focusing on the development of innovative drugs, was established in 1996 and is headquartered in Seoul, Korea with a US presence in Atlanta. ViroMed has assembled a diverse, but technologically and conceptually linked, pipeline of new and innovative therapeutics in the areas of cardiovascular and neurological diseases, cancers, and immune disorders, with 9 projects in clinical stages in the US, Korea, and China. Recently, ViroMed has successfully completed a phase II clinical study for diabetic peripheral neuropathy and critical limb ischemia (an extreme form of peripheral artery disease: PAD) in the US and Korea with a phase I/II clinical study for amyotrophic lateral sclerosis ongoing in the US. In China, a phase III clinical trial is underway for chemotherapy-induced thrombocytopenia. ViroMed is also running a botanical therapeutics program as a cash cow to balance the long-term biologics programs.

Representative Product – Biologics (Clinical trial)Product Target Disease Technology Country Development Stage

VM202-PAD Peripheral Artery Disease DNAUSA Phase II (Completed)

Phase III (Planned)KoreaChina

VM202-DPN Diabetic Peripheral Neuropathy DNAUSA Phase II (Completed)

Phase III (Planned)KoreaVM202-ALS Amyotrophic Lateral Sclerosis DNA US Phase I/II (Ongoing)

VM202-CAD Coronary Artery Disease DNA + Injection Catheter Korea Phase I (Completed)

Phase II (Planned)VM501 Thrombocytopenia Protein China Phase III (Ongoing)

VM206 Breast Cancer DNA+Virus Korea Phase I (Completed)Phase II (Planned)

VM202 – New and Innovative Drug for Cardiovascular and Neurological DiseasesVM202 is a DNA-based medicine designed to express two isoforms of the protein called hepatocyte growth factor (HGF). HGF is well known to induce the formation of new blood vessels and the growth and regeneration of nerve cells. Currently, VM202 is in clinical trials for 4 major cardiovascular or neurological diseases. In all studies, VM202 is delivered by a simple intramuscular injection around the affected site. 1 A double blind, placebo controlled, phase II study for critical limb ischemia (VM202-PAD) has been very successfully completed in the US and Korea, demonstrating that VM202 could increase blood flow and tissue perfusion, thereby effectively treating ischemia. 2 Another double blind, placebo controlled, phase II study for diabetic peripheral neuropathy (VM202-DPN) in the US and Korea has been completed last year, showing high pain reliving effect and potential to expand current market. The data was recently published in an international scientific journal. 3 After successful phase I trial for coronary artery disease (VM202-CAD), a phase II study is planned for 2015 in Korea. 4 VM202 has also been approved for a phase I/II trial for amyotrophic lateral sclerosis (VM202-ALS), also known as Lou Gerig’s disease, and is currently ongoing in the US.

VM206 – Therapeutic Cancer VaccineVM206 is a therapeutic cancer vaccine delivered through a simple intramuscular injection that induces an immune response against the tumor-associated antigen Her2/neu, found in several types of cancers such as breast cancer. A phase I clinical study for breast cancer has been successfully completed in Korea, showing that injecting VM206 could effectively induce both humoral (antibody) and cellular (CTL) immune responses against cancers. The product is being developed for patients who have received surgery and/or chemotherapy. A phase II trial is planned for Korea.

VM501 – Recombinant Protein for Chemotherapy-Induced Thrombocytopenia (CIT)The only drug approved for CIT by the US FDA is a recombinant interleukin 11 (IL-11) protein called Neumega. Its use has been highly limited because of serious side effects associated with this drug. VM501 is a genetically engineered interleukin 11 (IL-11) designed to produce a high level of efficacy, but with improved safety. After successful phase I and II studies, a phase III clinical study is currently ongoing in China.

· Company ViroMed Co., Ltd.· CEO Kim Yongsoo· Specialty

Business1) DNA/protein-based biopharmaceuticals2) Phytotherapeutics (botanical drugs/nutraceuticals)

· Head Office 5th Bldg 203, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul, Korea· Homepage www.viromed21.com

Pharmaceutical

Pharmaceutical

4544

Equipped with the state-of-the-art cGMP manufacturing facilities and extensive research capabilities, Yuhan is growing into a global pharmaceutical company offering one stop services from R&D to commercial production of intermediates, APIs, and finished products.

Yuhan has undergone successful audits by many international regulatory agencies such as the US FDA, the EU EMA/EDQM, the Australian TGA, and the Japanese PMDA. Yuhan’s overseas’ business activities include:

- New drug development projects with multinational partners. - Developing and optimizing cost effective synthetic processes for APIs and intermediates.

Yuhan is committed to deliver the best medicines to the world for improving the health and quality of human life. Beginning with the out-licensing to China of Yuhan’s ‘Revanex’, the world’s first acid pump agonist, Revanex is now supplied world-wide to markets in India and Southeast Asia. Yuhan is continuously expanding its overseas markets with finished products.

ProductsProduct/Project Indication Feature & Strength

Revanex Gastritis NCE drug, NDA (2007), World-first acid pump antagonist (APA)

YH4808 GERD NCE drug, on phase 2, 2nd generation APA. Fast onset-time and cleaner adverse effect profile than current PPI

YH12852 IBS NCE drug, expected to fulfill unmet medical needs for IBS treatment, Comparative advantage of efficacy and safety to current market players

R&D Pipeline

· Company Yuhan Corporation· CEO Jung hee, Lee· Specialty Pharmaceutical · Location 74 Noryangjinro Dongjak-gu, Seoul· Homepage http://www.yuhan.co.kr/Eng/index.asp

CONTACT US

Head Quarters74 Noryangjinro Dongjak-gu, Seoul, 156-754, Korea• Phone : +82-2-828-0181• Fax : +82-2-828-0300

Best Partner Best Yuhan

Yuhan Corporation

Supplement1. Products Expected to Export

2. Technology Transfer

3. Certifications from Health Authorities

Supplement

Supplement

4948

1. Products Expected to ExportCompany Product name Active Ingredient Indication Category Expected

country Note

Ahngook pharm.co.Ltd

Synatura syrupDried ivy leaf ext. + Coptis rhizome butanol dried ext.

Relief of cough and sputum due to acute respiratory infection, chronic inflammatory

bronchitisRespiratory

system drugs

Middle East Asia / Africa / South East

Asia/ L. America

entered into license agreement in America,

Mexico, Iran and EU including

CIS.

Anycough capsule Theobromine

Relief of cough symptoms caused by rhinitis, sinusitis, nasopharyngitis and acute &

chronic bronchitisRespiratory

system drugs

Middle East Asia / Africa / South East

Asia

entered into license agreement in EU and L.

America.

Letopra tablet S-Pantoprazole Treatment of reflux esophagitis (GERD) Digestive system drugs Global

Anytin SR tablet trimebutine maleate S.R

irritable bowel syndrome, functional dyspepsia, gastroduodenitis

Digestive system drugs

Global Except China

entered into license agreement in China.

Curost granules montelukast sodiumprevention and continuous therapy of

asthma, relief of perennial and seasonal allergy rhinitis

Respiratory system drugs Global

entered into license agreement in Vietnam

and Philippines.

Icopang syrup dried ivy leaf 30% ethanol ext.

Relief of cough and sputum due to acute respiratory infection, chronic inflammatory

bronchitisRespiratory

system drugs Global

BCWORLD PHARM. CO., LTD.

Mepem Inj. 1g Meropenem 1g Antibiotics Prescription Medicine

US, EU, Middle East

-

Sinraci Inj. 500mg Imipenem, Cilastatin sodium Antibiotics Prescription

Medicine -

Vitamin Inj. Tamiflumate Well-being products Prescription Medicine -

Morphine Sulfate Inj. Morphine Sulfate Narcotics Prescription

Medicine -

BC Atorvastatin Tab. Atorvastatin Calcium Lipid-Lowering agents Medicine -Remiba Inj. Remifentanyl HCl Narcotics Medicine -

BIONEER CORPORATION

SAMiRNATM-Survivin Synthetic drugs Solid cancer siRNA drug US, EU

SAMiRNATM-IPF/COPD

target genesSynthetic drugs IPF(Idiopathic Pulmonary Fibrosis)/

COPD(chronic obstructive pulmonary disease) siRNA drug US, EU, CN

SAMiRNATM-DN Synthetic drugs Dengue fever/ Dengue hemorrhagic fever siRNA drug

US, EU, East South Asia, South

America

BoryungPharm-

aceuticalco.,Ltd.

Kanarb Fimasartan Hypertension Prescription Medicine Global

Kanarb Combination

Fimasartan with HCTZ or CCB Hypertension Prescription

Medicine Global

ADmycin Doxorubicin Antineoplastics Prescription Medicine Global

Oxalitin Oxaliplatin Antineoplastics Prescription Medicine Global

Gelfos Colloidal Aluminum Phospate Gastric Hyperacidity Heartburn

Non-Prescription

MedicineGlobal

Stogar Lafutidine Gastric ulcer Prescription Medicine Global

Cinalong Cilnidipine Essential Hypertension Prescription Medicine Global

Chong Kun Dang

pharm-aceutical

Corp.

TacroBell Tacrolimus Immunosuppressant Prescription Medicine Worldwide

Duvie Lobeglitazone Anti-diabetics Prescription Medicine Worldwide

Leukivec Imatinib Anti-cancer Prescription Medicine Worldwide

Gemtan Gemcitabine Anti-cancer Prescription Medicine Worldwide

Belotaxel Docetaxel Anti-cancer Prescription Medicine Worldwide

Supplement

Supplement

4948

Company Product name Active Ingredient Indication Category Expected country Note

CJ HealthCare corporation

Moveloxin Inj. Moxifloxacin Infection Antibiotics

Cinezolid Tab&Inj. Linezolid Infection Antibiotics

Citopcin Inj. Ciprofloxacin Infection Antibiotics

Tapocin Inj. Teicoplanin Infection Antibiotics

Vancorin Inj. Vancomycin Infection Antibiotics

Epokine Inj. Erythropoietin Anemia Biologicals

Leukokine Inj. Filgrastim Neutropenia Biologicals

Pemta Inj. Pemetrexed Cancer Oncology

Calmtop Inj. Irinotecan Cancer Oncology

OmapOne Lipid Inj.Soybean oil

Olive oil, Fish oilMedium-ChainTriglycerides

Parenteral NutritionIV Solution(1-chamber

bag)

Generic of Smof Lipid®

OmapOnePeripheral Inj.

Lipid, Amino acid, Glucose Total Parenteral Nutrition (TPN)

IV Solution(3-chamber

bag)

Generic of Smof Kabiven

Peri®

Enteone Tab. Entecavir Hepatitis B infection Antiviral

Dae Hwa Pharm-

aceutical Co. Ltd.

Resnalin patch TulobuterolRespiratory distress caused by airway

obstruction of bronchial asthma, acute bronchitis, chronic bronchitis, or

emphysema

Prescription Medicine US, EU, etc. -

Aceren cap. Diacerein Rheumatoid arthritis, osteoarthritis Prescription Medicine US, EU, etc. -

Almetamine tab.Betamethasone,

Dexchlorpheniramine maleate

Urticaria, hay fever, allergic rhinitis, drug hypersensitivity reaction, chronic bronchial asthma, atopic dermatitis, eczema, contact dermatitis, allergic

conjunctivitis

Prescription Medicine US, EU, etc. -

Bidica tab. Biphenyl dimethyl dicarboxylate

Chronic persistent and active hepatitis that is associated with a high SGPT level or

drug-induced high transaminase level Prescription

Medicine US, EU, etc. -

Protase tab. Bromelain, Crystallized Trypsin

Fracture, sprain, internal, external and incarcerated hemorrhoid after proctoptosis

and a hemorrhoidal surgeryOTC Product US, EU, etc. -

Daewon Pharm. Co.,

Ltd.

Freefol MCT Inj. Propofol 1%, 2% General Anesthesia Narcotic Paraguay, Venezuela

Wontran ER Tab. Acetaminophen + Tramadol HCl Chronic and Acute pain Analgesic Guatemala

Pelubi Tab. Pelubiprofen Osteoarthritis, Rheumatoid, Lumbargo Analgesic Thailand

Megex-I Susp. Megestrol Acetate Anorexia Sex hormone Jordan

Oramin F Soft Cap. Multivitamin + Korean Ginseng Supplement of vitamins and minerals Multivitamin Kuwait

Nezelex Spr. Mometasone Furoate Allergic rhinitis Respiratory Russia

Daewoong Pharm-

aceutical. Co. LTD

Easyef Spray EGF Diabetic foot ulcer, oral mucositis, wounds biologics worldwide

Easyef Ointment EGF Acute wound biologics worldwide

Caretropin 22.5 IU hGH Growth hormone deficiency biologics worldwide

Eposis EPO Anemia in end stage renal disease biologics worldwide

Novosis BMP-2 Dental sinus lift graft biologics worldwide

Novosis – OS BMP-2 spinal fusion biologics worldwide

Nabota Botulinum toxin type A glabellar lines, upper limp spasticity biologics worldwide

Olostar Olmesartan + Rosuvastatin Concomitant hypertension and dyslipidemia

Value-added Generics & Generics

worldwide

URSA Ursodeoxycholic acid Liver & bile disease including cholestasis, Gallstone etc

Value-added Generics & Generics

worldwide

Albis Ranitidine + Bismuth + Sucralfate Gastric & duodenal ulcer, gastritis

Value-added Generics & Generics

worldwide

Dehecta Dioctahedral smectiteRelif of painful symptoms associated with

esophageal-gastric and large intestinal diseases, Acute/Chronic diarrhea

Value-added Generics & Generics

worldwide

Luphere Leuprolide Prostate cancer, Endometriosis, Precocious puberty

Value-added Generics & Generics

worldwide

Supplement

Supplement

5150

Company Product name Active Ingredient Indication Category Expected country Note

Daewoong Pharm-

aceutical. Co. LTD

Neovest Iopromide CT contrast mediaValue-added Generics & Generics

worldwide

Nurigra Sildenafil Erectile DysfunctionValue-added Generics & Generics

worldwide

Nurigra Chew Sildenafil Erectile DysfunctionValue-added Generics & Generics

worldwide

Mediclore poloxamer, gelatin, chitosan medical device - adhesion barrier medical device worldwide

GemVax & KAEL Co.,

Ltd.RIAVAX®

inj.Tertomotide

hydrochloride pancreatic cancer USA, China, Japan

GreenCrossCorp.

GreenGene F inj.Beroctocog alfa

(Blood coagulation factor VIII, recombinant)

For the prevention and control of bleedingepisodes and preoperative management in

Hemophilia ABiological Product

USA, Europe,Latin America,

Asia, Middle East,

etc

OngoingPh. III in

US &Europe

GCFLU inj.

Purified Inactivated Influenza Virus Antigen

Type A (H1N1)Purified Inactivated

Influenza Virus Antigen Type A (H3N2)

Purified Inactivated Influenza Virus Antigen

Type B

For the Prophylaxis against Influenza Biological Product

USA, Latin America,

Asia, Middle East,

etc

PQ from WHO & Procured through PAHO

Hunterase Idursulfase-ßFor patients with Hunter Syndrome(Mucopolysaccharidosis II, MPS II)as an enzyme replacement therapy

Biological Product

USA, Europe,Latin America,

Asia, Middle East,

etc

Orphan Drug

Designationgranted

from US FDA

Handok Inc.

Ketotop plaster Ketoprofen NSAID Small Molecule GlobalKetotop gel Ketoprofen NSAID Small Molecule Global

Calcium for BoneSeaweed

powder,Magnesium oxide,Vitamin D3

mixture

Bone & joint health management, osteoporosis

Health Functional Food Global

TripleCare11 kinds of Vitamine,3

kinds of Mineral, Omega-3

Circulation, Vitality Health Functional Food Global

SawpalmaxSaw palmetto naturalextract, Octacosanol

Prostate Health Functional Food Global

Eye-Omega3 Fish oil, Vitamin A, E Circulation & Eye health management Health Functional Food Global

MSM Jointcare Dimethyl sulfonate Multicare for Joint & Cartilage healthcare, Osteoporosis management

Health Functional Food Global

Hutos Joa TeunTeun

Zinc, Aloe, Chlorella andother mineral Immunity for Kids Health Functional

Food Global

Hutos Ara ssukssuk Chewable Omega 3 Circulation forkids Health Functional Food Global

Hutos Nado ssukssuk

Calcium, MagnesiumVitamine D Calcium supplement for kids Health Functional

Food Global

Hutos Moya banjjak

beta-Carontin, Chewable Eye healthcare management for kids Health Functional

Food Global

Hutos Multivitamin & Mineral

Multi-vitamine(13 kinds ofVitamin, 6 kinds of mineral)

Basic nutrition sate for kids Health Functional Food Global

Aquainnerskin Hyaluronic acide Skin Care Health Functional Food Global

Body styling Garcinia Cambogia Body Shape Health Functional Food Global

Probio Double Action Probiotics, Vitamine C Intestine Health Functional

Food Global

Good for Liver, Milk-thistle Care Q

Milk thistle (silymarin),Tumeric extract(Curcumin)

Liver + Vitality Health Functional Food Global

Full of Neutrient, Vitafood Q

13 kinds of Vitamine,8 kinds of Mineral,Curcumin

Multi-vitamin Health Functional Food Global

Supplement

Supplement

5150

Company Product name Active Ingredient Indication Category Expected country Note

Handok Inc.

Good for Circulation, Omega Q Omega-3, Curcumin Circulation, Improve triglyceride in blood Health Functional

Food Global

Ready Q Drink curcumin 50mgMango flavor fruit drink Hangover management General Food Global

Ready Q Chew curcumin 30mg,Chewable jelly Hangover management General Food Global

HANLIM PHARM. CO., LTD.

DAGES CAP Pepsin etc. Polyenzymatic digestant OTC Product China

TROPIN inj. Dopamine HCI Cardiovascular related agents

Prescription Medicine

Vietnam,Venezuela

etc.

POSOD EYE DROPS Potassium iodide,Sodium iodide Anticataratics Prescription

MedicineNigeria,

Vietnam etc.

NASAFLEXNASAL SPRAY

Mometasone furoate,

Azelastine HClAntiallergics Prescription

Medicine None

RISENEXPLUS TAB Risedronate,Cholecalciferol conc. Treatment of osteoporosis Prescription

Medicine None

PROTANEYE DROPS Latanoprost Antiglaucoma Prescription

MedicineNigerial,

Cambodiaetc.

Hanmi Pharm.

Amosartan Amlodipine + Losartan Hypertension FDC Brazil, CIS

Amosartan Plus Amlodipine + Losartan + Clorthalidone Hypertension FDC WW

Amorsartan Q Amlodipine + Losartan + Rosuvastatin Hypertension FDC WW

Tadalopine Amlodipine + Tadalafil Hypertension / ED FDC WW

Rosutib Rosuvastatin + Ezetimibe Dyslipidemia FDC WW

Esomezol Esomeprazole Strontium GERD IMD WW

HUONS CO., LTD.

Clacier Eye drop Cyclosporin 0.05% Dry eye syndrome Prescription Drug

EU, Oceania, North

America, Middle-East

Modified Generic

Valsarex Tablet Amlodipine 5mgValsartan 80mg Essential Hypertension Prescription

Drug EU BE study

Lercapin Tablet Lercanidipine HCL 10mg Lercanidipine HCL 10mg Prescription

Drug

South-EastAsia

Southwest Asia

-

Mucoramin Tablet Rebamipide 100mg Gastric ulcer, acute gastritis, acute aggravation of chronic acute

Prescription Drug

South-EastAsia -

Noreprin injection Norepinephrine bitartrate 8mg Myocardial infarction, Shock by sepsis Prescription

DrugAfrica

South-EastAsia

-

Pine injection 25000IU

Heparin sodium25,000IU/

5mLAnticoagulant Prescription

Drug

Latin America,Northeast

Asia-

HyundaiPharm-

aceuticalCo., Ltd.

Surfolase (Cap) acebrophylline Cough : acute and chronic bronchitis Respiratory Worldwide -

Levotuss(Tab, SYR) levodropropizine Cough : acute and chronic bronchitis Respiratory Worldwide -

Uremin(Tab) desmopressin acetate Nocturnal enuresis Urogenital

system Worldwide -

Drovan(Tab) ibandronate sodium Prevention of osteoporosis in

postmenopausal womenMusculo-

Skeletal system Worldwide -

Nebolmin(Tab) nebivolol Hypertension, Chronic heart failure Cardiovascular Worldwide -

IL-YANG PHARM-

ACEUTICAL CO., LTD.

SUPECT Cap. radotinib 2nd line of CML(chronic myeloid leukemia)-CP(chronic phase)

prescription medicine

Asia, EU and Lantin

America-

Noltec tab Ilaprazole Gastric Ulcer, Deodenal Ulcer, Erosive Esophagitis

prescription medicine

Asia, EU and Lantin

America-

ILYang Flu Vaccine Pre-filled

Syringe inj

Trivalent purified inactivated Influenza

virus antigenInfluenza Vaccine Vaccine Any -

Sol + LIQUID Taurine, Multi Vitamin Improves performance Beverage/Energy Drink Any -

WONBI-D LIQUID Korea Ginseng Improves Health OTC Product Any -

Supplement

Supplement

5352

Company Product name Active Ingredient Indication Category Expected country Note

ISU Abxis

Clotinab Abxicimab Anti-thrombotic orphan drugMiddle EastSouth East

Asia

Abcertin Imiglucerase Gaucher's disease orphan drugMiddle EastSouth East

Asia

Fabagal Agalsidase beta Fabry's disease orphan drug Latin America

JW Pharm-

aceutical

CarbapenemImipenem

MeropenemDoripenemErtapenem

Antibiotics API Global

Prepenem Inj. Imipenem Antibiotics Sterile injectable Global

Pospenem Inj. Meropenem Antibiotics Sterile injectable Global

CombiFlex Lipid Inj. Glucose, Amino acid,And Lipid Total Parenteral Nutrition I.V. solution Global

Linezolid Inj. Linezolid MRSA PremixI.V. solution Global

Levofloxacin Inj. Levofloxacin Antibiotics PremixI.V. solution Global

Hitraconazole Itraconazole Fungal Infection Tablet Global

Kolmar Korea

Co., Ltd.

ZERO-X Cap. Orlistat Anti-obesity Agents Prescription Medicine

EUSouth America

Asia-

GLITOL Tab. Miglitol Anti-Diabetics Prescription Medicine

EUAsia

Middle East-

MAXFORGE Tab. Valsartan and Amlodipine Antihypertensive Prescription

MedicineEU

AsiaMiddle Eas

-

Taminal Cap. Tamsulosin BPH PrescriptionMedicine

AsiaMiddle East

Africa-

Tacrolimus Ointment

Tacrolimus Ointment 0.1%, 0.03% Atopy Prescription

MedicineAsia

Middle EastAfrica

-

Korea United

Pharm. Inc.

Clanza®CR Tab Aceclofenac 200mg [M01A]Pain caused by rheumatism Prescription Medicine Global

Controlled Release

Formulation

Cilostan®CR Tab Cilostazol 200mg [B01C]Ischemic symptoms, Thrombosis Prescription Medicine Global

Controlled Release

Formulation

Clavixin®Duo Tab Clopidogrel 75mg and Aspirin 100mg [B01C]Acute coronary syndrome (antiplatelet) Prescription

Medicine Global Fixed Dose Combination

Kalomin®Tab Pelargonium sidoides ext. [R05C]Upper respiratory tract infections Prescription

Medicine Global New Dosage Formulation

Kuhnil Pharm-

aceutical Co.,Ltd

Vancomycin for inj. 500/1000 mg Vancomycin Antibiotics Prescription

Medicine worldwide

Teicoplanin for Inj. 200/400 mg Teicoplanin Antibiotics Prescription

Medicine worldwide

Omega-3/Rosuvastatin mini capsule 2000/5mg

Omega-3 + Rosuvastatin Cardiovascular system drugs Prescription

Medicine worldwide

Omega-3/Atorvastatin mini

capsule 2000/10mgOmega-3 +

Atorvastatin Cardiovascular system drugs Prescription Medicine worldwide

Pulmican respules 500μg Budesonide Drug for bronchial asthma Prescription

Medicine worldwide

LG Life Sciences,

Ltd.

EPO Erythropoetin Anemia in chronic renal disease Biological product

MENA,Brazil,Russia

-

rFSH recombinant FSH Infertility Biological product

MENA, Mexico, Brazil -

hGH human Somatropin Growth hormone deficiency Biological product

Mexico, Russia,

Southeast Asia-

Supplement

Supplement

5352

Company Product name Active Ingredient Indication Category Expected country Note

LG Life Sciences,

Ltd.

Hyruan plus/SIHA Hyaluronic acid Joint arthritis Medical deviceMENA,

Southeast Asia,

Eastern Europe-

Yvoire Hyaluronic acid Wrinkle correction Medical deviceMENA,

Southeast Asia,

Eastern Europe-

Medytox Inc.

Neuronox® Botulinum toxintype A

Blepharospasm, Focalspasticity in pediatric

cerebral palsy,Glabellar Wrinkles

Biological Product

(Prescription medicine)

ROW, etc.

Neuramis® Hyaluronic acid wrinkles Medical Device

US, EU,etc.

SamjinPharm-

aceuticalCo., Ltd.

PLATLESS Tablet Clopidogrel bisulfate Antithrombotic Prescription Medicine Worldwide -

BAMEDIN Tablet Rebamipide Treatment of gastroduodenal ulcers and gastritis

Prescription Medicine Worldwide -

NEUSTATIN-A Tablet Atorvastatin Calcium Antihyperlipidemia Prescription

Medicine Worldwide -

AIDBONE PLUS D Tablet

Alendronate sodium + Cholecalciferol Treatment of Osteoporosis Prescription

Medicine Worldwide -

Clopidogrel bisulfate (form 1) APIs Antithrombotic

Active Pharmaceutical

IngredientsWorldwide -

Rosuvastatin Calcium APIs HMG-CoA reductase inhibitor

Active Pharmaceutical

IngredientsWorldwide -

Pitavastatin Calcium APIs HMG-CoA reductase inhibitor

Active Pharmaceutical

IngredientsWorldwide -

Olmesartan medoxomil APIs Angiotensin II blocker

Active Pharmaceutical

IngredientsWorldwide -

SamyangBiopharm- aceuticals

Corporation

Genexol® PM Paclitaxel Anti-cancer Prescription Medicine

Russia, CSI, Africa,

South-America, etc.

Cremophor free

formulation

Nanoxel® M Docetaxel Anti-cancer Prescription Medicine Worldwide

Tween-80 free

formulation

Oncology Injectables

PaclitaxelDocetaxelOxaliplatin

Anti-cancer Prescription Medicine Worldwide Generic

Zolenic® Injection Zoledronic acid Anti-cancer Prescription Medicine Worldwide Generic

DemenCure® Patch Rivastigmine Dementia Prescription Medicine Worldwide Lower API

& same PK

Fentaderm® Patch Fentanyl Severe pain Prescription

Medicine Worldwide Lower API& same PK

Shin Poong Pharm.Co.,Ltd

Hyal Inj. Sodium hyaluronate Osteoarthritis Prescription Medicine world wide

Hyal Forte Inj. Sodium hyaluronate Osteoarthritis Prescription Medicine world wide

Varodipine Tab. Amlodipine besylate Anti-hypertension Prescription Medicine world wide

Hivix Tab. Clopidogrel bisulfate Anti-thrombotic Prescription Medicine world wide

Lozarsin Tab. Losartan potassium Anti-hypertension Prescription Medicine world wide

SK Chemicals

Co. Ltd.

Rivastigmine patch Rivastigmine Alzheimer’s disease Prescription medicine

EU, US, Asia, Latine

America, Middle east

Already exporting

to EU

Albumin Human albumin Hypo-albuminemiaPrescription

medicine(Blood product)

Asia, Middle east, Latine

America

Exporting to India,

China etc

Liv-Gamma(SN) Human immunoglobulin Agammaglobulinemia

Prescription medicine

(Blood product)

Asia, Middle east, Latine

America

Exporting to India, Thailand,

etc

Supplement

Supplement

5554

Company Product name Active Ingredient Indication Category Expected country Note

SK Chemicals

Co. Ltd.

Hepabulin IV Human anti-hepatitis B immunoglobulin post-exposure prophylaxis HBV exposure

Prescription medicine

(Blood product)

Asia, Middle east, Latine

America

NDA submitted in Korea

Trast Piroxicam Osteoarthritis, Tenosynovitis, Myalgia & others OTC product Asia, Latine

America

Exporting to some Asian

countries

Joins Clematis mandshurica & others Osteoarthritis Prescription

medicineAsia, Latine

America

Mvix Mirodenafil Erectile dysfunction Prescription medicine

Asia, Latine America

Tadalafil ODF Tadalafil Erectile dysfunctionPrescription

medicine(ODF)

Asia, Middle east, Latine

America

SK Chemicals

Co. Ltd.

Montelukast ODF Montelukast AsthmaPrescription

medicine(ODF)

Asia, Middle east, Latine

AmericaApproved in Korea

SKYCellflu Influenza vaccine Prevention for influenza virus (Cell culture) Vaccine Asia, Latine America etc.

Preparation for WHO

PQ

ST Pharm Co., Ltd.

API Montelukast Asthma API US, EU etc. -

API Stavudine anti HIV/AIDS API US, EU etc. -

API Terizidone anti Tuberculosis API US, EU etc. -

API Clopidogrel Bisulfate Anti-coagulant API US, EU etc. -

API Atovastatin Calcium Anhydrous Metabolic disease API US, EU etc. -

TAEJOON PHARM. CO., LTD.

Cyporin N Cyclosporine Dry eye Prescription medicine EU,US,Asia

MC Free Sodium CMC Dry eye Prescription medicine EU,US,Asia

Hyaluni Hyaluronic acid Dry eyes for the temporary relief of burning, irritation and discomfort

Prescription medicine EU,US,Asia

TJ Ultra Polyethylene Glycol Temporary relief of irritation and burning due to dryness of the eye

Prescription medicine EU,US,Asia

Xalost Plus Latanoprost plus Timo-lol maleate Anti-glaucoma Prescription

medicine US

Xalost Latanoprost Anti-glaucoma Prescription medicine US

Alpadine Olopatadine HCl Conjunctivitis Prescription medicine EU,US,Asia

Iobrix Iohexol Angiography Prescription medicine EU,US,Asia

Coolprep Polyethylen Glycol Bowel cleansing for x-ray and endoscopic examination

Prescription medicine EU,US,Asia

Lamina G Sodium Alginate Gastric & duodenal ulcer, erosive gastritis Prescription medicine EU,US,Asia

Yuhan Corporation

Duowell Tablet Telmisartan + Rosuvastatin

Treatment for htypertension and hyperlipidemia

Newfactam Bovine Lung Surfactant Treatment for respiratory distress syndrome of newborns

Almagate Suspension Almagate Antiacidic functions

Antiphlamine S Lotion

Methyl SalicylateL-menthol Anti-inflammatory agent

Yucla Tablet Amoxicillin + Clavulanate Potassium Antibiotics

3-Chamber TNA(Total Nutrient

Admixture)Glucose+Amino

acid+Lipid Supply of nutrition

Supplement

Supplement

5554

2. Technology Transfer

Company Category IndicationDevelopment Status Targeted

country NoteKorea Overseas

Ahngook pharm.co.Ltd

Sustained release Urology Completed Global

Bio-betterNeutropenia Research Global

Growth Hormone Deficiency Research Global

BCWORLD PHARM. CO., LTD.

Biologic Cancer Preclinical - US / EU -

Biologic Cancer Preclinical - US / EU -

small molecule hyperlipidemia Preclinical - US / EU -

small molecule Schizophrenia Preclinical - US / EU -

BoryungPharm-

aceuticalco.,Ltd.

New Chemical Entity(ARB: Fimasartan) Hypertension Launching Launching Global

Bukwang Pharmaceutical

Co., Ltd.

Small Molecule Cancer Phase 1/2a Phase 1/2a EU, Japan -

Nucleoside Hepatitis B virus Launched Launched NDA South America, EU -

Chong Kun Dang pharm-

aceutical Corp.

Small moleculeCamtobell Cancer Launched China, Taiwan,

Macau

Small moleculeDuvie Diabetes Launched Worldwide

Small moleculeCKD-516 Cancer phase 1

(completed) Worldwide

Small moleculeCKD-581 Cancer phase 1 Worldwide

biosimilarCKD-11101 Anemia Phase 3

(sanctioned) Worldwide

vaccineCKD-12201 HPV vaccine phase 1

(completed) China

CJ HealthCare corporation

CJ-12420 GERD Phase 2(Completed)

Phase 1(Completed)

China,South-East

AsiaNCE

VogMet®

(voglibose+metformin) Diabetes Launched N/AChina,

South-East Asia

IMD

Pemta® RTU(pemetrexed) Oncology Launched in 4Q

2015 N/A EU, Japan, China

RTU(ready-to-use) liquid

CJ-30056(atorvastatin+metformin Hyperlipidemia & Diabetes Phase II N/A EU, USA, China IMD

CJ-30059(candesartan+amlodipine Hypertension Phase III N/A EU, USA, China IMD

Crystal-Genomics,

Inc.

Small molecule Osteoarthritis ApprovedPhase IIa

completed (EU)

Worldwide

Small moleculeABSSSI, Osteomyelitis and other serious Staph

infections including MRSA-

Phase IIa completed

(USA)Worldwide

Small molecule Cancer Phase Ib/ 2 ready - Worldwide

Small molecule Cancer (hematologic) Preclinical Worldwide

Dae Hwa Pharm-

aceutical Co. Ltd.

Mucous membrane adsorptive composition which enables poorly soluble compounds to solubilize.

Cancer Phase 3 -USEUetc.

-

Manufacturing method of solubilize composition of paclitaxel Cancer Phase 3 -

USEUetc.

-

Percutaneous absorption product including diclofenac Analgesic Phase 3 -

USEUetc.

-

Manufacturing method of voglibose Diabetes Launching -USEUetc.

-

Composition of percutaneous absorption including Tulobuterol Respiratory Launching -

USEUetc.

-

Daewon Pharm. Co.,

Ltd.Analgesic Osteoarthritis, Rheumatoid,

Lumbargo O China

Supplement

Supplement

5756

Company Category IndicationDevelopment Status Targeted

country NoteKorea Overseas

Daewoong Pharm-

aceutical. Co. LTD

biologics Diabetic foot ulcer, oral mucositis, acute wounds launched launched worldwide

biologics Anemia in end stage renal disease launched launched worldwide

biologics Growth hormone deficiency launched launched worldwide

Genexine, Inc.

Gene & Stem Cell HPV Cervical Cancer Phase 2 Phase 2

Hybrid Fc Technology

Hemophilia Preclinical Preclinical

Autoimmune diseases Preclinical Preclinical

Growth Hormone Phase 2 Phase 2

Type 2 Diabetes Preclinical Preclinical

Anemia Phase 2 -

Neutropenia Phase 1 -

Handok Inc.

Small Molecule Glaucoma Discovery - Global

Biological Product Growth Hormone Deficiency Phase II Phase II Global

Biological Product Auto-inflammatory disorders Phase I - Global

HANLIM PHARM. CO., LTD.

Small molecule Age related Macular Degeneration Preclnical USA, EU

IMD Osteoarthritis Phase 2USA, EU, East

Asia, South America

IMD Hypertension Phase 1USA, EU, East

Asia, South America

IMD Perennial allergic rhinitis ApprovalJapan, EU, East

Asia, South America

Herbal Bronchitis Phase 2 Japan, EU, East Asia

Hanmi Pharm.

MetabolicDiseases

Diabetes/Obesity Phase II US/EU Phase II WW

Diabetes Pre-Clinical EU Phase I WW

Diabetes Pre-Clinical Pre-Clinical WW

Diabetes/Obesity Pre-Clinical EU Phase I WW

Endocrine Diseases Growth Hormone Deficiency in adults Phase II EU Phase II WW

Oncology

Neutropenia Phase I US/EU Phase II WW

Gastric Cancer Phase II - WW

Colorectal Cancer Phase I - WW

NSCLC, Gastric Cancer, Breast Cancer Phase II - WW

NSCLC Phase II - WW

Solid Tumor Phase I - WW

Gastric Cancer, Breast Cancer Phase I - WW

Autoimmune Rheumatoid Arthritis - EU Phase I WW

HUONS CO., LTD.

Prescription Drug Gastroesophageal reflux disease

Development completion/

Under BE study- America

Simplification of Manufacturing

process

Prescription Drug Essential Hypertension Under development - EU

Simplification of Manufacturing

process

Prescription Drug Hypotensive agent Development completion - CIS, EU IMD

HyundaiPharm-

aceutical Co., Ltd.

CNS Epilepsy PC - Worldwide -

GI Protective agent of the gastric mucous membrane PC - Worldwide -

IL-YANG PHARM-

ACEUTICAL CO., LTD.

prescription medicine2nd line of CML(chronic myeloid leukemia)-CP

(chronic phase)Launching - Any -

Supplement

Supplement

5756

Company Category IndicationDevelopment Status Targeted

country NoteKorea Overseas

IL-YANG PHARM-

ACEUTICAL CO., LTD.

prescription medicine Gastric Ulcer, Deodenal Ulcer, Erosive Esophagitis Launching Launching

(China) Any -

Vaccine Influenza Vaccine Launching - Any -

Biologic Ant-viral agent Pre-clinical - Any -

ISU AbxisAbcertin Gaucher's disease Launched

MAA in progress (a part of

Middle east and South America)

USA, EU

Fabagal Fabry's disease Launched NA USA, EU

JW Pharm-

aceutical

CWP291 Cancer Phase 1 Phase 1 Global

CreaVax-HCC Cancer Phase 3 - Global

URC-102 Gout Phase 2 - Global

Korea United

Pharm. Inc.

Controlled Release Formulation Analgesic Launched - Global

Controlled Release Formulation Antithrombotic Launched - Global

Fixed Dose Combination Antithrombotic Launched - Global

New Dosage Formulation Antitussive Launched - Global

Controlled Release Formulation Antithrombotic Clinical Trial - Global

Controlled Release Formulation GI modulator Clinical Trial - Global

Fixed Dose Combination Anti-hypertensive Clinical Trial - Global

Controlled Release Formulation Antitussive Clinical Trial - Global

LG Life Sciences,

Ltd.

Biologics Rheumatoid arthritis Phase 1 N/A Worldwide Antibody biosimilar

Small molecule Gout Phase 1 N/A Worldwide XO inhibitor

Small molecule Atherothrombosis Phase 1 N/A Worldwide P2Y12 inhibitor

Medytox Inc.

Biologics(Botulinum toxin product) Glabellar Wrinkles, etc. phase 3 - - -

Samjin Pharm-

aceutical Co., Ltd.

SA001 Dry eye syndrome Preclinical - Worldwide -

SA002 Obesity Preclinical - Worldwide -

SA003 Arthritis Preclinical - Worldwide -

SA004 Hyperlipidemia Preclinical - Worldwide -

SamyangBiopharm- aceuticals

Corporation

polymer-basedparenteral DDS

tech.Anti-cancer launching Ph 2 US, EU Solubility

enhancing

polymer-basedparenteral DDS

tech.Anti-cancer Ph 1 - US, EU

Solubilityenhancing,Sustained

release

TDS tech. Neuropathic pain Ph 2(completed) - US, EU

Better patient

compliance

TDS tech. Severe pain Ph 1 (completed) - US, EU Marketed

SiRNA DDS Anti-cancer Preclinical - US, EUSafe

polymer based DDS

Shin Poong Pharm.Co.,Ltd

SP-8203 Anti-stroke Clinical(P1) - world wide

KOREA MOTIE(Ministry

of Trade, Industry

and Energy) supported

Project

Medicurtain® Anti-adhension Launched Launched world wide

KOREA KDDF(Korea

Drug Development

Fund) supported Project

SP-35454 Osteoporosis - Clinical(P1) world wide

SP5M001 Osteo-arthrosis Clinical(P1) - world wide

SP5V003 Dermal filler Preclinical - world wide

Supplement

Supplement

5958

Company Category IndicationDevelopment Status Targeted

country NoteKorea Overseas

SK Chemicals

Co. Ltd.

ALK5 inhibitor Fibrotic disease Preclinical Preclinical Worldwide

GPR40 agonist Diabetes Preclinical Preclinical Worldwide

GnRH antagonistEndometriosis, uterine

myoma, BPH and breast / prostate cancers

Phase I Preclinical Worldwide

NCE407 Multiple Sclerosis Screening Screening Worldwide

NBP604 Hemophilia(rh. Factor VII) Preclinical Preclinical Worldwide

Leuprolide Microsphere Anticancer Formulation - Worldwide

Anastrazole Microsphere Anticancer Formulation - Worldwide

SID125 Erectile dysfunction NDA - Worldwide ODF

Montelukast ODF Asthma Launched - Worldwide ODF

SID141 Pain Screening - Worldwide Patch

SID143 Stroke, systemic embolism Screening - Worldwide Oral BA enhancing

SKYCellflu Prevention for influenza virus Pre-launch Worldwide

ViroMed Co., Ltd.

Plasmid DNA Perpheral Artery Disease Phase II (Completed)

US Phase II(Completed) Global

Plasmid DNA Diabetic Peripheral Neuropathy

Phase II (Completed)

US Phase II(Completed) Global

Plasmid DNA Amyotrophic Lateral Sclerosis - US Phase I/II

(Ongoing) Global

Plasmid DNA Coronary Artery Disease Phase I(Completed) Global

Recombinant Protein Chemotherapy Induced Thrombocytopenia -

China Phase III

(Ongoing)Global

Botanical drug Allergy

Yuhan Corporation

New chemical Entity gastroesophageal reflux disease phase 2 USA, EU, Asia

New chemical Entity irritable bowel syndrome Phase 1 USA, EU, Asia

New chemical Entity type 2 diabetes preclinical USA, EU, Asia

New chemical Entity degenerative disk disease phase 2 USA, EU

New bio medicine type 2 diabetes preclinical USA, EU

Supplement

Supplement

5958

3. Certifications from Health AuthoritiesCompany Product name Active Ingredient dosage form Indication International

certification Note

BoryungPharm-

aceuticalco.,Ltd.

Doxorubicin Doxorubicin API Oncology EU GMP scheduled

Fimasartan Fimasartan API Antihypertension EU GMP scheduled

Linezolid Linezolid API Antibacterials PMDA

Alacepril Linezolid API Cardiovascular PMDA

Pitavastatin Pitavastatin API Cardiovascular PMDA

Fexofenadine Fexofenadine API Antihistamine PMDA

Chong Kun Dang

pharm-aceutical

Corp.

Sepirom Ceftriaxone Sodium hydrate Injection Antibiotics PMDA certification

Rasenazolin Cefazolin sodium Injection Antibiotics PMDA certification

Pengood Bacampicillin hydrochloride Tablet Antibiotics PMDA certification

Kmoxilin Amoxicillin/ Potassium clavulanate Tablet Antibiotics Anvisa

certification

CJ HealthCare corporation

Ceftazidime inj. Ceftazidime Inj. Infection Japan DMF

Ceftriaxone inj. Ceftriaxone Inj. Infection Japan DMF

Best-Call® Cefmenoxime Hcl Inj. Infection Japan GMP Inspection

Supply APIs to a Japanese Company

First-Sin® Cefozopran Hcl Inj. Infection Japan GMP Inspection

Pan-Sprorin® Cefotiam Hcl Inj. Infection Japan GMP Inspection

Banan® tab. Cefopodoxime Tab. Infection Japan GMP Inspection

Supply bulk-products to a Japanese

companyBanan® dry syrup Cefopodoxime Syrup Infection Japan GMP Inspection

GemVax & KAEL Co.,

Ltd.RIAVAX® Tertomotide hydrochloride injection pancreatic cancer KGMP

Handok Inc.

Non-B-Lactam solid dosage

form- - - Jordan

Coated tablets Metformine HClGlimepiride - - Colombia

Amaryl M 1/250mg

Metformin HClGlimepiride

Film coated tablets Diabetes Ivory Coast

Ukraine

Amaryl M 2/500mg

Metformin HClGlimepiride

Film coated tablets Diabetes Ivory Coast

Ukraine

Amaryl M SR 2/500mg

Metformin HClGlimepiride

Film coated tablets Diabetes Ukraine

- - Film coated tablet - Taiwan

Certificate for

manufacturing line

- - Ointment - Taiwan

- - Capsule - Taiwan

- - Tablets -

Oman, South Africa,

Tanzania, Ethiopia, Yemen(non-anticancer, non-B-lactam)

- - Coated tablets - Brazil, Peru, Saudi Arabia

Hanmi Pharm.

Pidogle Tab. Clopidogrel napadisilate Tablet Antithrombotic agentEU GMP

certification(Germany BGV)

20092012

Solid formulation Eye bath drops

Syria GMPCertification 2012

Amosartan Tab.5/50mg, 5/100mg

Amlodipine camsylate Losartan K Tablet Hypertension

Kazakhstan GMP

certification2012

Esomezole Cap. 20mg, 40mg

Esomeprazole strontium tetrahdyrate Capsule Gastroesopha geal reflux disease

Kazakhstan GMP

certification2012

Supplement

Supplement

6160

Company Product name Active Ingredient dosage form Indication International certification Note

Hanmi Pharm.

Amosartan Tab.5/50mg, 5/100mg

Amlodipine camsylate Losartan K Tablet Hypertension Russia GMP

certification 2012

Cozaar XQ5/50mg, 5/100mg

Amlodipine camsylate Losartan K Tablet Hypertension Peru 2013

Solid formulation Eye bath drops GCC 2013

Amosartan Tab.5/50mg, 5/100mg

Amlodipine camsylate Losartan K Tablet Hypertension Ukraine 2014

HUONS CO., LTD.

Epilido cartridge 1.8mL

Lidocaine,Adrenaline

cartridge(injection) Dental Anesthetics PMDA

Sodium chloride injection 0.9% Sodium chloride Ampoule

(injection)Flushing compatible intravenous tubing system and in dwelling intravascular access devices.

US FDA (510K)

Isotonic Sodium chloride solution Sodium chloride

Plastic Ampoule(injection)

Diluent for injectable drug PMDA

20% Glucose for injection Glucose

Plastic Ampoule(injection)

Hypokalemia, cardiac collapse, glucose supplement during

hypoglycemia, Cerebral edema, Shock, Cardiac disease, Non-oral supplement of water, Diagnosis of

diabetes

PMDA

IL-YANG PHARM-

ACEUTICAL CO., LTDl

IYEN2000 Taurine 2000, others Bottle Vitamin, Mineral & NutritionJapan

Non-sterile Quasi-Drug

GMP-

JW Pharm-

aceutical

Imipenem, Cilastatin

CefmetazoleAPI - Antibiotics Japan GMP

Prepenem Inj. Imipenem monohydrate and Cilastatin sodium Injection Antibiotics Japan GMP

ANVISA

Pospenem Inj. Meropenem trihydrate Injection Antibiotics ANVISA

Itraconazole SD Itraconazole Solid Dispersion Fungal Infection Japan GMP

Toracona Itraconazole Tablet Fungal Infection Japan GMP

LG Life Sciences,

Ltd.

Factive Gemcifloxacin Tablet Antibiotics FDA GMP certification -

hGH human Somatropin Injection Growth hormone deficiency FDA GMP

certificationEU GMP

certification-

Euvax B Hepatits B vaccine Injection Hepatits B vaccineWHO GMP certification

EU GMP certification

-

Euforvac-Hib DTP-HepB-Hib vaccine Injection DTP-HepB-Hib vaccine WHO GMP certification -

Hyruan plus Hyaluronic acid Injection Joint arthritis CE certification -

Medytox Inc.

Biologics(Botulinum toxin

product)Botulinum toxin

type AVial

(lyophilized)Glabellar

Wrinkles, etc.cGMP & EU GMP

SamyangBiopharm- aceuticals

Corporation

ActivePharmaceutical

Ingredient

PaclitaxelDocetaxel

Synthetic PaclitaxelPemetrexed

API Anti-cancerEU(Germany)

GMP certification

2014

Docetaxel(API) Docetaxel API Anti-cancerJapan(PMDA)

GMP certification

2013

Oncology Injectables

Oncology Injectables Injection Anti-cancer

EU(Germany)GMP

certification2012

Oncology Injectables

Oncology Injectables Injection Anti-cancer

Japan(PMDA) GMP

certification2010

Supplement

Supplement

6160

Company Product name Active Ingredient dosage form Indication International certification Note

SamyangBiopharm- aceuticals

Corporation

Paclitaxel(API) Paclitaxel API Anti-cancerJapan(PMDA)

GMP certification

2010

DiclofenacPatch

Diclofenac diethylammonium Plaster NSAIDs

Australia (TGA)GMP

certification2010

Shin Poong Pharm.Co.,Ltd

PYRAMAX® Pyronaridine & Artesunate Tablet Anti-malaria EU GMP Certification

Divaltan Tab. Valsartan - Anti-hypertensive agents JGMP(PMDA) API

Newtinib Filim-Coated Tab. Imatinib Mesylate - Anti-Neoplastics JGMP(PMDA) API

SK Chemicals

Co. Ltd.

OMED Omeprazole Tablet Anti-ulcer Germany(EU)

Rivastigmine Patch Rivastigmine Patch Alzheimer’s disease Germany(EU)

Plasma derivatives Blood product IRAN

ST Pharm Co., Ltd.

- Zidovudine API anti HIV/AIDS US FDA GMP-API -

- Zidovudine API anti HIV/AIDS PMDA GMP-API -

- Zidovudine API anti HIV/AIDS TGA GMP-API -

- Zidovudine API anti HIV/AIDS ANVISA GMP-API -

TAEJOON PHARM. CO., LTD.

Xalost Plus Latanoprost plus Timolol maleate Solution Anti-glaucoma EU GMP

certification

Xalostplus Latanoprost Solution Anti-glaucoma EU GMP certification

MC Free Sodium CMC Solution Dry eye CE Marking

Yuhan Corporation

API 1 API 1 - USFDA, TGA raw material

API 2 API 2 - USFDA, TGA, PMDA raw material

API 3 API 3 - USFDA, TGA, PMDA raw material

PMH PMH - USFDA, TGA raw material

Ribavirin Ribavirin - USFDA, EDQM raw material

Voglibose Voglibose - PMDA raw material

Cilostazol Cilostazol - PMDA raw material

Levofloxacin Levofloxacin - PMDA raw material

Piperacillin Piperacillin - PMDA medicine

mem

o

6362

mem

o

6362

mem

o

PB64